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 Recent advances in directed neuronal differentiation and reprogramming of pluripotent stem cells 
(PSCs) and somatic cells currently allow to obtain and study functional human neurons in vitro for 
both scientific and medical purposes. 
 Chemical stimulation with morphogens, growth factors and small molecules for in vitro 
differentiation of neurons recapitulates the neurodevelopmental patterning principles that are 
observed in the early embryo. 
 Overexpression of key-lineage specific transcription factors allow to induce dramatic changes in 
transcriptional networks that drive cellular conversions towards neurons. 
 Chromatin modifiers, epigenetic editing and RNA interference (RNAi) allow to induce profound 
epigenome remodelling processes that underlie cell fate switches. 
 Although various challenges remain to be overcome in order to realise their full potential, the 
availability of human neurons in in vitro has critical implications for future brain-related studies 
and the development of therapeutic interventions for many brain disorders.  
 
Abstract 
Human pluripotent stem cell (PSC) technology and direct somatic cell reprogramming have 
opened up a promising new avenue in the field of neuroscience. These recent advances allow 
researchers to obtain virtually any cell type found in the human brain, making it possible to 
produce and study functional neurons in laboratory conditions for both scientific and medical 
purposes. Although distinct approaches have shown to be successful in directing neuronal cell 
fate in vitro, their refinement and optimization, as well as the search for alternative approaches, 











populations. Furthermore, we are currently limited in the number of neuronal subtypes whose 
induction is fully established, and different cultivation protocols for each subtype exist, making it 
challenging to increase the reproducibility and decrease the variances that are observed between 
different protocols. In this review, we summarize the progress that has been made in generating 
various neuronal subtypes from PSCs and somatic cells, with special emphasis on chemically 
defined systems, transcription factor-mediated reprogramming and epigenetic-based approaches. 
We also discuss the efforts that are being made to increase the efficiency of current protocols and 
address the potential for the use of these cells in disease modelling, drug discovery and 
regenerative medicine.  
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Over the last decades, our general knowledge on human brain functions has grown 
exceedingly thanks to the availability of animal models and human brain tissue. Although 
their utility is undeniable, both are challenged with limitations that have been impeding 
progress in gaining complete mechanistic insights, as well as in the development of 
therapeutic interventions for many brain disorders (Nestler and Hyman, 2010). The numerous 
transgenic animal models that have been established mimic pathological mechanisms of the 
human brain to some extent, but they do not yet satisfactorily capture human disease 
phenotypes completely (Nestler and Hyman, 2010). An animal is obviously not a human 
being and interspecies differences might, therefore, be critical factors underlying the failure of 
translating a wealth of preclinical findings into clinical implementations (Akhtar, 2015; Mak 
et al., 2014). Aside from the distinct (epi)genetic backgrounds, there are major physiological 
differences that could affect the development of disease phenotypes or differentially affect 
drug mechanisms, leading to misinterpretation of experimental findings. Human brain tissue 
samples, on the other hand, can generally only be obtained post-mortem, which complicates 
the study of disease aetiology and progression, since they simply do not allow to discriminate 
between cause and consequence of the disorder (Lewis, 2002). Cellular in vitro model 
systems, however, have the potential to overcome this latter challenge, owing to the 
possibility of manipulating the (epi)genetic architecture, as well as the environmental 
exposome, in culture conditions, which allows to study cause-effect relationships of 
pathological hallmarks in a controlled setting. Unfortunately, many early in vitro model 
systems have heavily relied on a combination of non-neuronal human cell lines, primary 
rodent cultures and transgenic rodent cell lines, which, similar to animal models, also all 














In view of the aforementioned limitations and the unmet necessity of finding therapeutic 
interventions for brain disorders, the recent availability of human pluripotent stem cell (PSC) 
technology and somatic cell reprogramming has offered new opportunities for human brain-
related studies (Pasca et al., 2014; Shi et al., 2016). PSC technology is an umbrella term that 
encompasses both embryonic stem cells (ESCs) and induced PSCs (iPSCs) (Yap et al., 2015). 
Aside from being derived from humans, the distinct advantages that these cells have are their 
unlimited proliferative capacity and the ability to differentiate towards virtually any cell type, 
including specific neuronal subtypes (Haston and Finkbeiner, 2016). These characteristics 
equip PSCs with the unique feature to provide a theoretically inexhaustible and replenishable 
source of cells in vitro. Somatic cells on the other hand, albeit restricted by their limited 
proliferative potential, can be obtained relatively easy from healthy individuals and patients, 
and can then be directly reprogrammed towards desirable neuronal subtypes in a comparative, 
but faster framework (Hou and Lu, 2016). Consequently, PSCs, somatic cells and their 
differentiated progeny can nowadays be used to model disease mechanisms in a humanized-
setting, where they allow for the investigation of unique human cellular and molecular 
features in a cell-specific and personalised matter (Riemens et al., 2017). In fact, we are 
currently in the middle of an exciting era where human PSC and somatic cell reprogramming 
studies are contributing to the understanding of underlying neurobiological processes, as well 
as the consequences of personal molecular variations on the development and course of brain 
disorders (Hou and Lu, 2016; Young-Pearse and Morrow, 2016). In addition, iPSC- and 
somatic cell-derived neuronal populations provide a platform for high-throughput drug 
screening and toxicity testing in an upcoming epoch of personalised medicine, which assists 
the production of therapeutic interventions and might at the same time provide cues for 














harbour therapeutic potential in the field of regenerative medicine, since they might be used 
for transplant therapies (Riemens et al., 2017). 
Given the heterogeneity of neuronal cells found in the human brain and the complex 
interactions between them, one of the main opportunities PSC technology, directed 
differentiation and somatic cell reprogramming are offering, is the study of multicellular 
neural cultures organized in a manner reminiscent to what is seen in distinct anatomical 
structures of the brain. Such a method offers a promising approach to study higher-order 
neuronal networks during development and allows studying single neuron connectivity, as 
well as various other cellular interactions found in the neuronal niche, such as those between 
glial cells and endothelial cells (Canfield et al., 2017; Kirwan et al., 2015). Another major 
focus  in the scientific community that emerges from the unique contributions each of the 
neuronal subtypes have in specific brain functions and disease, has been to obtain and study 
pure populations of neurons free of other subtypes. Derivation of such homogenous 
populations is especially important for the study of disease-associated neurons, where 
confounding effects of other subtypes should be avoided, such as in transcriptomic- and 
epigenetic profiling for example. Furthermore, the acquisition of protocols that can produce 
highly pure populations of neurons can in turn be utilized to customize the features of a 
multicellular culture. Successfully directing differentiation and cellular reprogramming in 
vitro has, therefore, been an area of intense research during the past two decades (Mertens et 
al., 2016). Many strategies have been explored utilizing mouse and human PSCs, as well as 
somatic cells, to generate anatomically specified neural precursor cells (NPCs) and 
differentiated neuronal subtypes (See Figure 1). As a definition used here, NPCs refer to the 
mixed population of cells consisting of all undifferentiated progeny from neural stem cells, 
therefore including both neural stem cells and neural progenitor cells. Altogether, these 














occur in the early embryo (Mertens et al., 2016). Thus, an improved understanding of 
developmental signalling pathways and gene regulatory networks has guided the design of 
neuronal differentiation and cellular reprogramming strategies (Yap et al., 2015). Although 
significant advances have been made, in vitro neuronal differentiation is actually not a process 
that is fully disciplined yet, as very often other cell types are produced in parallel to what was 
first intended by the researcher. Furthermore, differentiation protocols for multiple neuronal 
subtypes remain either unestablished or unstable, or they do not allow to obtain the terminally 
differentiated neuron with its entire functional maturated characteristics (Maroof et al., 2013; 
Zhang et al., 2013).  
To date, the majority of directed neuronal differentiation and direct somatic cell 
reprogramming protocols involve chemical stimulation through patterning cues or the use of 
ectopic overexpression of lineage-specific transcription factors that are known for their 
genuine involvement during neural development (Denham and Dottori, 2011; Erceg et al., 
2008; Vierbuchen et al., 2010). Although it is currently accepted that these networks of 
patterning molecules and transcription factors orchestrate neuronal induction and 
differentiation, it is becoming more and more evident that cell-intrinsic mechanisms are also 
key players within these circuits (Gifford et al., 2013; Lunyak and Rosenfeld, 2008; Qin et 
al., 2016). Neuronal induction and differentiation generally rely on the interplay of activation 
and inhibition on multiple developmental signalling pathways tightly controlled by the 
epigenetic machinery (Imamura et al., 2014; Yap et al., 2015). Within these networks, the 
epigenetic machinery is essential for fine-tuning genetic programs that coordinate distinct 
developmental processes, as well as shaping the neuronal identities at a phenotypic resolution 
(Feng et al., 2007; Fitzsimons et al., 2014). With the current advances in epigenetic editing 
(Kungulovski and Jeltsch, 2016; Liu et al., 2016; Thakore et al., 2016) and RNA interference 














differentiation and direct somatic cell reprogramming has become available. Such approaches 
allow the design and construction of novel specific artificial epigenetic pathways or the 
redesign of existing endogenous molecular systems, in order to intentionally change 
epigenetic information at desired loci (Jurkowski et al., 2015). Those systems can now be 
used as an additional tool to guide neuronal cell fate in vitro and also allow to address 
fundamental questions concerning the role of epigenetics in assigning neuronal cell fates. 
In the present review, we will provide an overview on the progress made in generating 
various neuronal subtypes from PSCs and somatic cells in vitro. We will dissect the current 
used chemically defined systems, transcription factor-mediated reprogramming methods and 
epigenetic-based approaches. Furthermore, we will discuss the efforts that are being made to 
increase the efficiency of current protocols and highlight the potential for the use of this 
platform in disease modelling, drug discovery and regenerative medicine. 
2. Chemically defined systems  
2.1 Neural induction and differentiation 
Research to develop protocols for the differentiation of PSCs into clinically relevant cell 
subtypes has progressed at a rapid pace. Hundreds of protocols have become available that 
allow to obtain early NPCs and eventually the derivation of desired neuronal populations 
(Chambers et al., 2009; Erceg et al., 2009; Erceg et al., 2010; Karumbayaram et al., 2009; 
Shi, 2013; Ying et al., 2003). In the classical embryoid body (EB) method, scientists let PSC 
form self-assembling aggregates from dissociated suspension cultures, known as EBs 
(Denham and Dottori, 2011; Karanfil and Bagci-Onder, 2016). This method initially aimed to 
spontaneously differentiate the PSCs into mixed cellular populations encompassing the three 
germ-layers (Itskovitz-Eldor et al., 2000). As PSCs readily differentiate into many different 














neuronal production, as well as further selection procedures, are usually necessary to increase 
the homogeneity of a specific neuronal subpopulation (Abranches et al., 2009). The second 
method to reconstitute neural commitment in vitro and to achieve efficient neural induction 
from PSCs has relied upon adherent monolayer culture differentiation, which eliminates the 
use of multicellular aggregations (Chambers et al., 2009; Shi, 2013; Ying et al., 2003). In this 
method, PSCs are dissociated into single cells and further cultured with conditioned media 
that also enhances neuronal conversion. Various aspects of the monolayer differentiation 
protocol have been extensively studied, adapted and optimized recently by different research 
groups, currently allowing neural induction within a few days (Günther et al., 2016; Yan et 
al., 2013). The third method to promote neural induction from PSCs can be achieved by co-
cultivation of PSCs with stromal cell feeder layers (Kawasaki et al., 2000; Shi, 2013). Co-
culturing PSCs with other cell types is based on the idea that these surrounding cells provide 
cues that assign cell fates along the neural lineage. The use of stromal feeder layers is, 
however, only an efficient PSC differentiation strategy for certain neuronal subtypes, such as 
dopaminergic neurons (Lim et al., 2015). Additional efforts on optimising previous methods 
have recently also lead to the establishment of a combinatory approach for PSC differentiation 
that is characterised by a chemically transitional EB-like state (Fujimori et al., 2017). A low 
density monolayer culture on a feeder is differentiated under appropriate culture conditions 
and induces intermediate progenitor cells with the capability of differentiating into the three 
germ layers. The main advantage of this approach is that it harbours a reduced innate 
differentiation propensity of PSCs, even if the PSCs are known for their unfavourable 
differentiation (Fujimori et al., 2017).  
Although different strategies for neuronal conversion in PSCs have been explored, the general 
trend moves towards stromal-free methods combined with chemically defined culture 














patterning molecules, such as morphogens and growth factors, which force enrichment of the 
desired neuronal cells. Additionally, an increasing number of studies have also illustrated the 
use of small molecules and emphasized their significant benefits for neural induction and 
differentiation in PSCs, as well as for somatic cell reprogramming (Zhang et al., 2012). Aside 
from providing positive signals to induce neuronal fates, many of these factors also inhibit 
signalling pathways that control the differentiation into other germ layers then the ectoderm. 
Of note, just as in vivo embryonic development can be broken down into distinct stages where 
distinct patterning molecules are required to induce neuronal cell fates, so too can the in vitro 
specification of differentiating neuronal population from PSCs (Davis-Dusenbery et al., 
2014). The compositions of the chemically defined media, as well as the compound 
concentrations at any given time point, can, therefore, significantly redirect the anatomical 
and functional identity of the differentiating cells.  
Neuronal conversion follows the neural induction principle that is first initiated by removing 
medium components that promote self-renewal, which on itself is sufficient to trigger 
differentiation towards all the three embryonic germ layers (Tao and Zhang, 2016). Inhibition 
of extraembryonic and meso-endoderm differentiation can be further enhanced by culturing 
the cells in serum-free medium and by the actions of early patterning molecules, through 
which the PSCs progressively start restricting their differentiation potential towards the neural 
lineage to form early NPCs (Pasca et al., 2014; Tao and Zhang, 2016). Many neural induction 
protocols include the simultaneous inhibition of transforming growth factor beta (TGF-
β)/Activin/Nodal and bone morphogenic protein (BMP) signalling pathways, i.e. dual SMAD 
inhibition, which is similar to what is observed in vivo (Chambers et al., 2009; Patani et al., 
2009). Inhibition of the TGF-β and BMP pathways is thought to promote differentiation of 
PSCs along the neural lineage primarily through inhibition of PSC self-renewal, as well as by 














Consequently, signalling molecules such as Noggin (NOG), left-right determination factor 
(Lefty)-1, Lefty-2, Dickkopf-1 (DKK1), TGF-β inhibitor SB431542, glycogen synthase 
kinase 3 beta (GSK3β) inhibitor CHIR99021 and BMP inhibitor dorsomorphin homolog 1 
(DMH-1) have all been used to promote neural induction from PSCs (Goulburn et al., 2012; 
Li et al., 2011). Other pathways, including epidermal growth factor (EGF), fibroblast growth 
factor (FGF) and wingless-type MMTV integration site family (WNT) signalling, have been 
described to regulate neuronal differentiation by promoting induction and survival of the 
NPCs (Davis-Dusenbery et al., 2014; Dhara and Stice, 2008). In particular, FGF2 has been 
shown to enhance the neural induction phase and to increase the number of NPCs, whereas 
omitting it during subsequent stages promotes their differentiation into mature neurons 
(Wilson et al., 2000).  
After neural induction, second series of lineage-specific patterning molecule cocktails have 
been used to direct the further differentiation of the NPCs towards mature neuronal subtypes. 
Although the availability of protocols for subtypes within specific neurotransmitter classes is 
limited and different cultivation conditions for each of these classes exist, protocols for 
glutamatergic, dopaminergic, γ-aminobutyric acid (GABA)-ergic, serotonergic, and 
cholinergic motor neurons have become available over the years (See Table 1) (Eiraku et al., 
2008; Goulburn et al., 2012; Lee et al., 2007; Lu et al., 2016; Yan et al., 2005). Specification 
of the NPCs takes place both along the rostral-caudal and the dorsal-ventral axes of the brain, 
coordinated by the synergistic actions of temporally and spatially available patterning 
molecules (Imaizumi et al., 2015). The presence and concentrations of these molecules define 
the transcriptional code and, hence, the identity of the NPCs in a particular domain along both 
axes. NPCs are generally specified first in the head region and extend caudally, meaning that 
they become committed to an anterior forebrain fate by a default programme (Tao and Zhang, 














method, carry a rostral identity that is free of caudal markers (Tao and Zhang, 2016). Indeed, 
this anterior phenotype is transient and NPCs will take on a definitive regional identity 
depending on further cues. Treatment with increasing concentrations of sonic hedgehog 
(SHH) has shown to promote ventralization of the NPCs, while addition of retinoic acid (RA) 
promotes caudal fates (Davis-Dusenbery et al., 2014) and activation of WNT signalling exerts 
a dose-dependent effect where increasing concentrations are patterning the NPCs to forebrain, 
midbrain, hindbrain and anterior spinal cord identities, respectively (Davis-Dusenbery et al., 
2014; Kirkeby et al., 2012; Tao and Zhang, 2016). Although it remains largely unknown how 
all the patterned NPCs acquire functional and anatomical specificity, it is this regional 
patterning principle recapitulating in vivo morphogenesis that guides PSC neuronal 
differentiation in vitro (See Figure 2) (Liu and Zhang, 2011). Moreover, a specific 
neurotransmitter subtype can often be generated in different parts of the human brain and at 
different stages, demonstrating that different spatiotemporal cues can likely converge on the 
same terminal selectors and thereby induce a similar terminal fate (Gabilondo et al., 2016).  
The anatomically directed differentiation processes seen in these neuronal differentiation 
protocols are characterized by the same expression and temporal regulation of lineage-specific 
transcription factors as observed in vivo (Davis-Dusenbery et al., 2014). For instance, NPCs 
differentiated towards forebrain neurons carry an anterior identity by expressing PAX6 and 
OTX2, but not more caudal markers like EN1, GBX2 or HOX (Chambers et al., 2009; Tao and 
Zhang, 2016; Zhang et al., 2001). Thus, expression levels of these transcription factors 
represent useful markers that are widely used to assess the differentiation status of the cellular 
population (See Table 1). Furthermore, extensive gene expression analysis, 
electrophysiological characterization, biochemical assessments, and in vivo transplantation 
into rodent brains have been applied to examine the population characteristics, as well as 














these protocols, in vitro-directed differentiation in PSCs still results in highly variable 
neuronal populations with fluctuating yields of neuronal cells and remarkable differences in 
efficiency (Zhang and Jiang, 2015). This variability emerges from clear differences between 
the protocols, such as the neuronal induction method used, the chemical compositions of the 
media, the compound concentrations and the chemical exposure times that were used, as well 
as more undefined differences, including the culture densities and the passage number for 
example (Davis-Dusenbery et al., 2014). 
2.2 Glutamatergic neurons 
Despite the differences in developmental principles that underlie the specification of their 
subpopulations, excitatory glutamatergic neurons can be found throughout the whole central 
nervous system, such as in the cerebral cortex (Costa and Muller, 2014), as well as in 
subcortical regions like the thalamus (Song et al., 2015), and even in the spinal cord among 
others (Thomas Cheng, 2010). To date, strategies that have been established to successfully 
generate glutamatergic neurons from PSCs (See Table 1) are mainly based on the derivation 
of cortical glutamatergic neurons of which the vast majority originates from dorsal 
telencephalic regions (Li et al., 2009). As mentioned earlier, forebrain identity is a default 
programme for neuronal differentiation of PSCs, and existing protocols yield neurons with a 
glutamatergic identity without the need of an extra second series of patterning molecules. 
However, attributed to endogenous SHH signalling, mouse ESCs have been shown to 
differentiate into anterior NPCs with a ventral phenotype under serum- and morphogen-free 
culture conditions, resulting in a neuronal population of which only a minority was considered 
to be glutamatergic (Gaspard et al., 2008). Consequently, inhibition of intrinsic SHH 
signalling with the small molecule cyclopamine has been shown to prevent ventralization of 
the mouse NPCs and significantly increases the derivation of dorsal glutamatergic neurons 














that mouse ESCs cultured in the presence of retinoic acid (RA) induced highly homogenous 
neuronal populations, which, similar to previous report, where consistent with an identity of 
cortical pyramidal neurons (Bibel et al., 2004). Pyramidal neurons constitute more than 80% 
of the cerebral cortex neurons and are further diversified in distinct cortical layers that 
establish specific patterns of axonal output and dendritic input, providing the essential 
substrate of cortical circuitry (Espuny-Camacho et al., 2013). In a study by Eiraku et al. 
(2008) for example, it was also demonstrated that human ESC-derived cortical neurons 
stained positive for transcription factors corresponding to the development of the cortical 
layers in a temporal manner, including RELN, TBR1, CTIP2 and CUX1. However, opposite 
to the ventral phenotype observed in mouse ESCs, human PSCs have shown to differentiate 
by a default programme into synchronised populations of NPCs that predominantly express 
anterior dorsal markers (Gaspard et al., 2008; Li et al., 2009). This dorsal phenotype has been 
attributed to expression of endogenous WNT ligands, and, as a consequence, inhibition of 
WNT signalling or activation of SHH signalling has shown to almost completely convert 
primitive dorsal telencephalic NPCs to ventral progenitors at the expense of glutamatergic 
neuron identity (Li et al., 2009).  
Various studies have also addressed the potential of using the derived glutamatergic cultures 
for fundamental research. Kim et al. (2011c) suggested an approach for efficient 
differentiation of human glutamatergic neurons based on a spin EB protocol in ESCs and 
iPSCs. Interestingly, when co-cultured with human embryonic kidney cells (HEK293T) 
expressing NLGN3 and NLGN4, but not those containing autism-associated mutations, the 
iPSC-derived neurons were able to form functional synapses, demonstrating that these 
neuronal populations are a potential model for the study of synaptic differentiation and 
function under normal and disorder-associated conditions (Kim et al., 2011c). Also in their 














an anterior dorsal forebrain character by a default pathway. While addition of the SHH 
agonist purmorphamine (PUR) during the EB stages ventralized the NPCs, inhibition of SHH, 
however, did not enhance expression of dorsal markers as seen in mouse ESCs (Kim et al., 
2011c). Consistent with this finding, a more recent study also showed that cyclopamine 
treatment was not required for induction of the dorsal telencephalic fate in a human PSC 
monolayer system (Espuny-Camacho et al., 2013). By determining the time of onset for the 
expression of layer-specific markers during the course of differentiation, it was demonstrated 
that most of the pyramidal neurons generated here displayed an identity corresponding to deep 
cortical layers, while upper layer neurons were underrepresented (Espuny-Camacho et al., 
2013). This contrasts with a more recent report describing a robust culture system in human 
ESCs for the generation of both electrophysiological active deep- and upper-layer pyramidal 
neurons in equivalent proportions that were cultured in the presence of retinoids (Shi et al., 
2012a; Shi et al., 2012b). In the context of dual SMAD inhibition, they found that vitamin A 
is crucial for the efficient induction of cortical NPC differentiation and subsequent cortical 
neurogenesis. These findings agree with previous report (Bibel et al., 2004), which 
demonstrated that derivatives of retinoids have important roles in the acquisition of NPCs and 
telencephalic glutamatergic neurons from mouse ESCs. By using this approach, the efficiency 
of cortical neural induction from PSCs even approaches 100% (Shi et al., 2012b). Although 
various organisations are still missing, such as interactions with glial cells that are essential 
partners in synaptic functioning, these systems provide the first steps towards functional 
studies of human cerebral cortex development and the generation of patient-specific cortical 
networks in vitro. These future applications will be particularly interesting for modelling 
disorders that are known for their cortical synaptic dysfunctions, including epilepsy, 
schizophrenia and dementia, and allow high-throughput testing for therapeutic interventions 














2.3 GABAergic neurons 
Various subtypes of inhibitory GABAergic neurons exist in the brain and spinal cord, which 
can be categorised based on their developmental origins, localization, synaptic connections, 
co-expression of molecular and neurotransmitter markers and electrophysiological properties 
(Liu et al., 2013). During development, GABA interneurons are synaptically integrated into 
neuronal networks in the forebrain that originate mostly from the medial ganglionic eminence 
and, to a lesser extent, from the ventral lateral ganglionic eminence and the anterior dorsal 
ganglionic eminence (Fishell and Rudy, 2011; Liu et al., 2013; Nobrega-Pereira et al., 2008). 
These GABAergic NPCs migrate by following radial or tangential pathways, they 
differentiate into post-mitotic neurons and make connections with local glutamatergic neurons 
(Kriegstein and Noctor, 2004; Liu et al., 2013; Marin and Rubenstein, 2003). The vast 
majority of forebrain GABAergic interneuron progenitors express Nkx2-1 (Sussel et al., 1999) 
in addition to the telencephalic transcription factor Bf1, also known as Foxg1 (Goulburn et al., 
2012), and they can be distinguished from other types of GABAergic neurons, including the 
striatal GABAergic projection neurons, which originate from the lateral ganglionic eminence 
(Campbell, 2003; Liu et al., 2013). Forebrain GABA interneurons can be divided into many 
subgroups on the basis of molecular markers and their expression of neuropeptides or 
calcium-binding proteins, including somatostatin (SST), parvalbumin (PV), calretinin, 
calbindin and neuropeptide Y, although the medial ganglionic eminence progenitors mostly 
give rise to SST and PV interneurons (Liu et al., 2013).  
The majority of studies on the differentiation of GABAergic neurons in vitro have focused on 
guiding PSCs toward ventral telencephalic NPCs, primarily defined by the co-expression of 
Bf1 and Nkx2-1 (See Table 1) (Goulburn et al., 2012; Li et al., 2009; Watanabe et al., 2005). 
As stated in the previous section of glutamatergic neurons, ventral telencephalic pecursors 














leading to a neuronal population that is enriched in cortical GABAergic interneurons 
(Gaspard et al., 2008).Ventralization of human dorsal telencephalic NPCs on the other hand, 
has been achieved by addition of concentrated SHH or inhibition of WNT by DKK1 together 
with low concentrations of SHH, leading to the generation of enriched populations of human 
cortical GABAergic interneurons (Li et al., 2009). Interestingly, various groups have tried to 
purify the generated GABAergic NPCs using cellular selection systems. For instance, Maroof 
et al. (2010) described a protocol for the generation of cortical GABAergic interneurons from 
mouse ESCs based on EB formation and SHH signalling. In this study, a Lhx6-GFP bacterial 
artificial chromosome reporter construct was used, which allowed for the isolation and 
enrichment of the newly generated NPCs. Using a similar approach with a previously 
established NKX2-1::GFP human ESC reporter line, two other groups  (Maroof et al., 2013; 
Nicholas et al., 2013) have developed a protocol based on the combination of small molecules 
with the timed activation of SHH signalling. In both studies they showed that the human PSCs 
develop into GABAergic interneurons with mature physiological properties, both in vitro, as 
well as after transplantation into rodent brains. Liu et al. (2013) on the other hand, have 
described a protocol without transgenic modification or cell sorting that involves treatment 
with SHH or its antagonist PUR for directed GABAergic differentiation of human PSCs with 
high efficiency. After 2 weeks of differentiation, more than 90% of the neurons were 
estimated to be GABAergic interneurons, which was confirmed by immunostaining and 
electrophysiological analysis (Liu et al., 2013).  
Aside from the cortical GABAergic interneurons, several studies have also managed to 
acquire striatal GABAergic projection neurons, also known as medium spiny neurons (Carri 
et al., 2013). In one of the procedures, neural induction via BMP/TGF-β inhibition was 
coupled with exposure to SHH and DKK1 to drive ventral telencephalic specification in 














spiny neurons (Carri et al., 2013). Authenticity of the resulting neuronal population was 
monitored by the appearance of BF1/GSX2-positive progenitor cells typical for the lateral 
ganglionic eminence, followed by appearance of CTIP2-, FOXP1- and FOXP2-positive cells. 
These precursor cells then matured into MAP2/GABA-positive neurons with 20% of them co-
expressing DARPP-32 and CTIP2, and also carried electrophysiological properties expected 
for fully functional medium spiny neurons (Carri et al., 2013). Most recently, a reliable and 
simplified two- and three-step protocol to derive striatal GABAergic neurons from 
immortalized NPCs has also been established, using valproic acid (VPA) or SHH and DKK1, 
respectively (Lin et al., 2015). The differentiated cells expressed appropriate GABAergic 
markers and responded to ionotropic glutamate receptor stimulation. In accordance, the cells 
also expressed various glutamate receptor subunits and released GABA upon stimulation (Lin 
et al., 2015). In relation to disease modelling, the derivation of these GABAergic neurons 
represents a possible critical resource for the study of Huntington’s disease and Rett syndrome 
for example (Lin et al., 2015; Tang et al., 2016).  
2.4 Dopaminergic neurons 
Dopaminergic neurons are localized in the diencephalon, mesencephalon and the olfactory 
bulb (Chinta and Andersen, 2005), although the most prominent group resides in the 
mesencephalon, containing approximately 90% of the total number of brain dopaminergic 
neurons (Chinta and Andersen, 2005). Differentiation protocols for dopaminergic neurons, in 
particular for the ones originating from the midbrain, have received a lot of attention due to 
their applicability into regenerative medicine for Parkinson’s disease, with numerous 
differentiation protocols published over the last years (See Table 1) (Ono et al., 2007; Pasca et 
al., 2014; Placzek and Briscoe, 2005). Studies in mice have shown that dopaminergic 
midbrain NPCs are specified from the floor plate in the mesencephalon, which is located at 














NPCs are transcriptionally characterised by the expression of Lmx1a, Foxa2, En1 and Otx2, 
and are controlled by two regulatory feedback loops also involving WNT and SHH signalling 
(Chung et al., 2009; Xi et al., 2012). In more detail, WNT1 induces expression of Otx2, which 
represses Gbx2 to coordinate the mid-hindbrain organizer and represses Nkx2-2, which 
defines the midbrain dopaminergic NPC domain from the lateral located progenitors of 
serotonergic neurons (Prakash et al., 2006). Thereby, it induces the expression of Lmx1a 
which either induces the pro-neural gene Ngn2 through Msx1 or inhibits the NPCs from 
acquiring alternative cell fates by repressing Nkx6-1 (Andersson et al., 2006; Chung et al., 
2009).  
It is this developmental principle in mice described above that currently also forms the 
guideline for differentiating midbrain dopaminergic neurons from human PSC (Xi et al., 
2012). However, initial reports for the differentiation of dopaminergic neurons have also 
heavily relied on the use of PA6 and MS-5 feeder cells (Barberi et al., 2003; Kawasaki et al., 
2000; Lim et al., 2015). Furthermore, studies have shown the successful differentiation of TH 
(tyrosine hydroxylase)-expressing neurons from mouse ESCs and iPSCs based on chemically 
defined systems that relied on the generation of EBs (Lee et al., 2000;) and the activation of 
key signalling pathways by SHH and FGF8, a morphogen important for the formation of the 
isthmus (Barberi et al., 2003; Lee et al., 2000; Pasca et al., 2014; Ye et al., 1998). Gradually, 
studies have tailored and applied these initial studies in primate (Xi et al., 2012) and human 
iPSCs (Cai et al., 2010;; Swistowski et al., 2010; Yan et al., 2005), and demonstrated efficient 
induction of neurons with a dopaminergic phenotype. Importantly, in most of the previous 
mentioned reports it was actually not conclusively determined whether the obtained TH-
positive neurons were really representing midbrain dopaminergic neurons, at least they did 














SHH had the potency to induce the dopaminergic identity but was possibly not sufficient to 
restrict the neurons to the midbrain fate (Xi et al., 2012).  
A better understanding of essential signalling pathways and transcriptional networks 
important for dopaminergic neuron midbrain differentiation, as well as their more precise 
temporal implementation, has improved the protocols over time. Incorporation of WNT/β-
catenin signalling due to the availability of the GSK3β inhibitor CHIR99021 eventually led to 
an improved midbrain specification in a reliable and efficient manner (Arenas et al., 2015; 
Denham et al., 2012; Doi et al., 2014; Kirkeby et al., 2012; Kriks et al., 2011; Xi et al., 
2012). This was first demonstrated by Kriks et al. (2011), who produced cultures containing 
around 75% of floor plate-derived dopaminergic neurons, assessed by immunostaining of 
markers such as FOXA2 and TH. Further expression analysis in this study also demonstrated 
abundant co-expression of lineage-specific genes necessary for appropriate dopaminergic 
neuron specification (Kriks et al., 2011). Furthermore, the cells were able to be efficiently 
engraft in rodent brains and survived in vivo without overgrowing, a phenomenon that was 
previously only observed with very poor performance using human PSC-derived 
dopaminergic neurons (Kriks et al., 2011). Their findings were later also confirmed in 
different human ESC lines, iPSCs, and rhesus monkey iPSCs, showing that a narrow range of 
CHIR99021 at a particular developmental stage restricts the cells to form midbrain floor plate 
progenitors which, in the presence of FGF8, acquire a dopaminergic neuron identity (Xi et al., 
2012). Based on the latter approaches, differentiated dopaminergic populations from 
Parkinson’s disease patient-derived iPSCs have even demonstrated to mimic several 
pathological mechanisms of the neurological disorder in vitro (Fernandez-Santiago et al., 
2015; Woodard et al., 2014). Interestingly, disease phenotypes were only observed in the 














significance of directed dopaminergic differentiation protocols for disease modelling in vitro 
(Woodard et al., 2014).  
2.5 Serotonergic neurons 
Serotonergic neurons are found in the raphe nuclei that arise from progenitors in the 
rhombencephalon during development and can be divided into two main clusters: A rostral 
division located just caudal to the isthmus and a more caudal division situated in the 
myelencephalon (Deneris and Gaspar, 2018). While the rostral division has widespread 
innervating projections throughout the brain, the caudal division mainly projects down to the 
spinal cord (Deneris and Gaspar, 2018). These primary anterior and posterior clusters are 
further segmented along the rostro-caudal axis according to 9 rhombomeric divisions, where 
specific transcriptional codes confer positional identities. For instance, the progenitors located 
at rhombomeric segments 2–3 are distinguished from segment 1 by expression of Hoxa2 but 
not En1, while progenitors in segment 4 express Phox2b, leading into an intervening gap 
between cluster 3 and 5, where serotonergic identity is repressed and visceromotoneurons are 
formed instead (Alenina et al., 2006; Lu et al., 2016). Specification of the distinct segments is 
thought to be induced by different combinations of morphogen gradients of which the most 
important ones include SHH, FGF8 and FGF4 (Vadodaria et al., 2016). In addition, WNT- 
and TGF-beta signalling have also been shown to be important for determining boundaries 
and specifying a hindbrain fate (Dias et al., 2014; Kirkeby et al., 2012; Rhinn and Brand, 
2001). Developing serotonergic NPCs gradually start expressing Nkx2-2, Ascl1 and Foxa2, 
which constitutes a primary gene regulatory network for serotonergic specification (Deneris 
and Gaspar, 2018). Although it is evident that their postmitotic neurons in different regions 
are transcriptional and functional heterogeneous, this primary genetic cascade activates a 














GATA3, INSM1, LMX1B and PET1 in mice or FEV in humans, which is key in their 
terminal specification (Deneris and Gaspar, 2018).  
Thus far, there have been only few attempts to differentiate serotonergic neurons in 
chemically defined systems from PSCs (See Table 1). Mice studies have given primary 
knowledge on the combinations of developmental signals that allow the generation of 
serotonergic neurons in vitro (Vadodaria et al., 2016). One of the first approaches to induce 
serotonergic neurons from ESCs was based on the formation of EBs in combination with the 
activation of SHH and FGF8 signalling (Lee et al., 2000). The protocol was primarily 
intended to enrich for dopaminergic neurons, resulting in considerably low yields of 
serotonergic neurons (±11%) compared to the total neuronal population (±72%). Mouse ESCs 
have then also been co-cultured with stromal cells in the presence of SHH and FGF4, yielding 
a substantially higher proportion (±57%) of serotonergic neurons (Barberi et al., 2003). More 
recently, a simplified method to generate serotonergic neurons from mouse PSCs in 
monolayer cultures has also been developed (Shimada et al., 2012). The cells were cultured 
on a layer of matrigel in the presence of NOG, a BMP inhibitor, and reached 80% pure 
serotonergic cultures after cell sorting (Shimada et al., 2012). Although their approach 
increased the homogeneity of serotonergic neurons and appears to be an appealing simpler 
alternative to culturing mouse ESCs on feeder cells, effectively only ±6% of the initial 
neuronal cells were considered serotonergic, which remains a relatively low proportion of 
cells that can be generated from mouse PSCs in vitro.  
Studies have consequently demonstrated that the key developmental signalling molecules 
involved in serotonergic differentiation could also be applied for directing their differentiation 
utilizing human PSCs. One of the first protocols established in order to obtain serotonergic 
neurons from human ESCs was based on the induction and enrichment of NPCs that 














(Kumar et al., 2009). In this study, neural differentiation was estimated to be around 20% 
with up to 70% of all neurons staining positive for serotonin (5-HT), generating 14% of 
serotonergic neurons in vitro. Interestingly, acidic FGF, which is localized in raphe neurons in 
rats (Stock et al., 1992), and 5-HT, which is known to contribute to the development of 
serotonergic neurons in vivo (Migliarini et al., 2013), were added to the growth factor cocktail 
for differentiation and maturation of the NPCs. Using a differentiation protocol based on 
FGF8 and SHH, another study (Vadodaria et al., 2015) found that approximately 8% of the 
differentiating human ESCs committed to a serotonergic fate, which was determined by a co-
staining of 5-HT and tryptophan hydroxylase (TPH).  
Thus, although these first protocols in mice and human PSCs were very promising, they only 
met limited success considering their low yields, which limits the ability to use these cells for 
further applications. However, most recently, Lu et al. (2016) were the first to develop a 
robust chemically defined system to induce human iPSC to enriched populations of 
serotonergic neurons with very high efficiency. Induction of ventral hindbrain NPCs was 
achieved by maintaining PSCs in medium containing SB431542, DMH-1 and CHIR99021. 
Following neural induction, the NPCs were exposed to FGF4 together with SHH to promote 
the acquisition of a serotonergic cell fate, eventually reaching more than 60% serotonergic 
neurons (Lu et al., 2016). The key aspect here, is the activation of the WNT pathway by 
CHIR99021 that, within a narrow window of concentrations, gives rise to ventral hindbrain 
NPCs that further differentiate into serotonergic with a typical identity for rhombomeric 
divisions 2-3. Interestingly, treatment with the FDA-approved antidepressants tramadol and 
escitalopram oxalate in this latter study resulted in release or uptake of 5-HT in a dose- and 
time-dependent manner, which emphasized their utility for the evaluation of drug candidates 














depression and a common target for antidepressants (Licinio and Wong, 2016; Sierksma et 
al., 2010).  
2.6 Cholinergic motor neurons 
Cholinergic motor neurons can be broadly divided into two main groups according to the 
location of their cell body: (I) Upper motor neurons located in the motor regions of the 
cerebral cortex, and (II) lower motor neurons, which are located in the brainstem and spinal 
cord (Davis-Dusenbery et al., 2014). Upper motor neurons have ascending pathways to lower 
motor neurons, which project to the musculature, where they control muscle contractions via 
neuromuscular junctions (Davis-Dusenbery et al., 2014). Spinal motor NPCs originate from a 
highly restricted foci in the ventral neural tube in response to RA, FGFs and SHH (Patani, 
2016). These cells express the basic helix-loop-helix transcription factor Olig2, which, 
together with Ngn2, direct the expression of motor neuron fate consolidating genes such as 
Hb9 and Isl1. For a more detailed description of the underlying developmental cascade that 
results in the acquisition of these cells, we would like the reader to refer to other excellent 
reviews (Davis-Dusenbery et al., 2014; Patani, 2016). Motor neurons can be further 
developmentally allocated to discrete motor columns, which extend along the rostral-caudal 
neural tube and contain motor neuron pools that are responsible for innervating a single 
skeletal muscle, each of which is also arranged by an anatomical logic corresponding to their 
targets (Patani, 2016). Retinoid signalling plays key roles in the diversification of motor 
neuron subtypes from the common NPC pool and additionally contributes to spinal cord 
columnar organisations, which are then again characterized by unique transcriptional codes 
that define the regional identity of the neuronal subtypes (Patani, 2016). 
By recapitulating the developmentally rationalized programme of morphogenic cues, 
considerable advances using chemically defined systems have primarily been made in 














in vitro motor circuitry in the contexts of motor neuron disease and spinal cord injury has 
been motivating the attempts to produce motor neurons for translational research (Davis-
Dusenbery et al., 2014). Initial studies have outlined methods to derive functional cholinergic 
motor neurons from mice (Barberi et al., 2003) and human ESCs (Lee et al., 2007; Li et al., 
2005; Singh Roy et al., 2005), while more recent studies have applied similar methods to 
human iPSC lines (Dimos et al., 2008; Karumbayaram et al., 2009; Qu et al., 2014; Shimojo 
et al., 2015). The numerous protocols that have been developed utilize various directed 
differentiation methods, including co-culture with stromal feeders (Barberi et al., 2003; Lee et 
al., 2007), adherent monolayer cultures (Qu et al., 2014), or the use of EB induction followed 
by neuralization, cholinergic neuron differentiation and neuronal maturation (Karumbayaram 
et al., 2009; Shimojo et al., 2015). In most cases, studies have reported the use of RA 
treatment with addition of recombinant SHH or small molecule agonists of the SHH 
signalling pathway to induce differentiation of PSCs into cholinergic motor neurons. 
Patterning NPCs by RA and SHH confers caudal and ventral anatomical identities, 
respectively, and gives rise to OLIG2 expressing neurons, which in turn begin to express 
CHAT, HB9 and ISL1 (Shimojo et al., 2015). Cholinergic motor neurons obtained through 
these methods have been shown to possess numerous characteristics of their in vivo 
equivalents, including electrophysiological properties, the possibility to engraft into the 
developing spinal cord and the presence of correctly labelled neuromuscular junction 
complexes, demonstrating the potential ability to form functional muscular junctions in vitro  
(Davis-Dusenbery et al., 2014). However, in contrast to the generic developmental principles 
that allow cholinergic motor neuron specification, the process determining how individual 
motor neuron subtypes can be generated is relatively less well understood (Davis-Dusenbery 
et al., 2014). Nevertheless, in the context of mouse ESC differentiation for example, protocols 














character, as judged by expression of Hoxc5 and Hoxc6, but not Hoxc8 (Wichterle et al., 
2002). In the context of human motor neuron differentiation on the other hand, a recent report 
demonstrated a shift in the proportion of motor neurons expressing the median motor column 
marker LHX3 or the lateral motor column marker FOXP1, when SHH signalling was 
activated via a combination of smoothened agonist (SAG) and PUR instead of recombinant 
SHH (Amoroso et al., 2013). This sensitivity of the differentiating NPCs emphasizes the need 
for thorough evaluation of the differentiation protocols and also presents the opportunity for 
the optimization of motor neuron subtype specification (Davis-Dusenbery et al., 2014).  
3. Transcription factor-mediated reprogramming  
3.1 Cellular reprogramming and transdifferentiation 
For long it was thought that cellular differentiation and lineage commitment were irreversible 
processes established during embryonic development (Vierbuchen and Wernig, 2011). 
However, the cloning of animals by nuclear transfer demonstrated that maturated molecular 
mechanisms are reversible and that a nucleus from the most differentiated cell bears the 
potential to generate an organism (Vierbuchen and Wernig, 2011). These cell fusion 
experiments have proved that transcriptional reprogramming can occur by exposing a distinct 
nucleus to cytoplasmatic components of cells from distinct lineages, although the exact 
mechanisms underlying these processes remain challenging to address. Substantial interest in 
transcriptional reprogramming has been rejuvenated upon the discoveries by Dr. Takahashi 
and Prof. Dr. Yamanaka, who provided the foundation that somatic cells can be 
reprogrammed to iPSCs. The cells were initially generated by reprogramming fibroblasts via 
recombinant overexpression of four transcription factors, including Oct3/4, Sox2, Klf4, and 
Myc (OSKM, Yamanaka factors) (Takahashi and Yamanaka, 2006). The use of only four 
transcription factors was sufficient to induce dramatic cell fate changes and to reprogram fully 














substantially adapted and improved by using other sets of transcription factors, including 
LIN28 and NANOG (Yu et al., 2007), by introducing non-integrative transgene expression and 
by using different types of somatic cells (Schlaeger et al., 2015; Takahashi and Yamanaka, 
2016). Earlier work on the other hand, has demonstrated that increased activity of a single 
transcription factor, namely Myod1, is sufficient to directly convert fibroblasts into myocytes 
by a process known as transdifferentiation (Weintraub et al., 1989). This has supported the 
notion that cell fate conversions can be direct without the need of precedent de-differentiation. 
Consequently, these studies have raised the question whether transcription factor-mediated 
reprogramming could also directly induce neuronal fates in somatic cells or even PSCs (See 
Figure 3).  
Notably, and especially important in the context of disease modelling, these direct conversion 
modalities may prove to be invaluable in the study of late-onset neurodegenerative disorders 
because the age of somatic cells is maintained in the converted neurons, thus allowing to 
model the aging process in vitro (Mertens et al., 2015). In addition, while chemically defined 
differentiation protocols in PSCs are known for their long multistep protocols, PSCs exposed 
to specific sets of transcription factors have shown to differentiate much faster without 
additional culturing steps, therefore providing an appealing, simpler and possibly more 
effective differentiation strategy for PSCs in vitro (Busskamp et al., 2014). One of the major 
disadvantages of direct somatic cell reprogramming compared to directed differentiation of 
PSCs however, is that the former skips the pluripotent state and does not allow expansion of 
the cells before further applications, thereby limiting the accessibility of cells readily available 
in vitro. Nevertheless, somatic cell reprogramming into an intermediate state that allows 
substantial proliferation, such as NPCs, has already been considered (Hou and Lu, 2016; 
Raciti et al., 2013). For instance, mouse and human fibroblasts have been partially 














capable of differentiating into both neuronal and glial cells in the presence of leukemia 
inducible factor (LIF) and FGF2 (Matsui et al., 2012). The direct differentiation of partially 
reprogrammed cells may be useful for rapidly preparing high numbers of NPCs that could be 
expanded before terminal differentiation into target neurons.  
3.2 Induced glutamatergic neurons 
Starting from a pool of nineteen candidates, Vierbuchen et al. (2010) were the first to identify 
a combination of only three transcription factors, including Brn2, Ascl1, and Myt1l (BAM), 
which could rapidly and efficiently convert mouse embryonic fibroblasts (MEF) into induced 
neuronal (iN) cells (See Table 2). These iN cells expressed multiple neuron-specific markers, 
generated action potentials and were able to form functional synapses (Vierbuchen et al., 
2010). Electrophysiological recordings demonstrated that mainly excitatory postsynaptic 
potentials could be recorded, providing functional proof that a large majority of the iN cells 
exhibited a glutamatergic phenotype. Some cells also expressed GABAergic markers at 
earlier time points, including Gaba and Gad67, suggesting that both neuronal subtypes could 
be obtained but culture conditions probably favoured the glutamatergic phenotype 
(Vierbuchen et al., 2010; Vierbuchen and Wernig, 2011). These findings in murine somatic 
cells led to follow-up experiments using human fibroblasts, which eventually led to the 
successful generation of human iNs with the addition of Neurod1 to the BAM pool (Pang et 
al., 2011). Just like the generation of iPSCs, during that time it was thought that a 
combination of factors was necessary to fully reprogram iN cells from fibroblasts and the use 
of a single transcription factor was considered insufficient (Chanda et al., 2014). However, 
later it was shown that Ascl1 alone is satisfactory to generate populations of pre-dominantly 
glutamatergic iN cells from mouse and human fibroblasts, as well as ESCs (Chanda et al., 
2014; Mall et al., 2017). A clear hierarchical role of the reprogramming factors has, therefore, 














program, whereas access of BRN2 to the chromatin is apparently more cell-context-dependent 
and facilitates reprogramming later on (Chanda et al., 2014). Moreover, although Ascl1 alone 
is sufficient to generate iNs, endogenous Mytl is subsequently induced during reprogramming, 
and exogenous Myt1l has, therefore, demonstrated to greatly improve the efficiency of 
reprogramming and the functional maturity of the resulting iN cells (Mall et al., 2017). In 
fact, it has been shown that MYT1L exerts its pro-neuronal function by direct repression of 
many different somatic lineage programs except the neuronal program. This repressive 
function of MYT1L is mediated via recruitment of a complex containing SIN3B by binding to 
a previously uncharacterized N-terminal domain (Mall et al., 2017). In addition, knockdown 
of Myt1l in primary postmitotic neurons removed the repression of non-neuronal programs 
and impaired neuronal gene expression and function, indicating that many somatic lineage 
programs are actively and persistently inhibited by MYT1L to maintain neuronal identity 
(Mall et al., 2017). Aside from fibroblast, for murine astrocytes (Heinrich et al., 2010), mouse 
ESCs (Chanda et al., 2014; Thoma et al., 2012) and human PSCs (Chanda et al., 2014; Zhang 
et al., 2013), it has also been shown that single neurogenic factors, such as Neurod1 and 
Ngn2, alone are sufficient to rapidly induce the neuronal fate. Although Ascl1-induced iN 
cells displayed slower maturation kinetics at early developmental stages, their functional 
properties and neuronal gene-expression profile at later time points are surprisingly similar to 
that of Ngn2 or BAM iN cells (Chanda et al., 2014). 
After the establishment of the BAM pool and the other neurogenic transcription factors, 
researchers have been attempting to derive other neuronal subtypes by transcription factor-
mediated reprogramming and, thanks to that, additional factors have been identified with the 
ability to induce dopaminergic neurons, GABAergic neurons, serotonergic neurons, 
cholinergic neurons and adrenergic neurons (See Table 2) (Colasante et al., 2015; Mong et 














defined systems, all of these obtained cultures have been subjected to various bioassays and 
assessments in order to examine their population characteristics (See Table S2). Furthermore, 
studies have demonstrated that supplementation of chemically defined systems with 
transcription factor-mediated reprogramming can significantly increase the efficiency of 
obtaining differentiated neuronal cells, as well as vice versa (Hester et al., 2011; Kim et al., 
2011b; Mong et al., 2014). Notably, blockade of TGFb/SMAD signalling using Noggin and 
molecules such as SB431542 and LDN193189, as well as pharmalogical promotion of 
calcium signalling with cAMP and Forskolin have not only shown to increase iN yield, but 
have also been used to successfully generate transgene-free iNs (Gascón et al., 2017; 
Vadodaria et al., 2016; Xie et al., 2017). The fast progress in the field of chemically-mediated 
reprogramming and transdifferentiation provides us new ways to manipulate neuronal fates 
both in vitro and in vivo. These methods on their own and/or in combination with other 
approaches may accelerate the eventual applications of patient-specific human neurons 
generated in vitro, by facilitating the potency and timelines of the protocols, and by aiding in 
the specification of regional subtypes within neurotransmitter classes.  
3.3 Induced dopaminergic neurons 
By combining the BAM factors with Lmx1a and Foxa2, which are typically expressed in 
midbrain dopaminergic NPCs, human fibroblasts have been converted into induced 
dopaminergic (iDA) neurons (Pfisterer et al., 2011). This provided proof-of-principle that 
other subtypes of iN cells can be produced by transcription factor-mediated fate instructions. 
Since then, iDA neurons have been obtained by ectopic overexpression of various 
combinations of transgenes encoding midbrain-specific transcription factors (See Table 2). 
For instance, a minimal set of three transcription factors, i.e. Ascl1, Nurr1 and Lmx1a, was 
sufficient to generate functional iDA neurons from murine and human fibroblasts (Caiazzo et 














iDA neurons that were highly enriched in genes of the dopaminergic phenotype, released 
dopamine, exhibited proper electrophysiological profiles, and, in case of the murine iDA 
neurons, were able to integrate into neonatal mouse brains. Interestingly, the endogenous Th 
and Vmat2 promoter regions were highly demethylated in the iDA neurons, whereas they 
were fully methylated in the fibroblasts, indicating their epigenetic reactivation during 
dopaminergic conversion (Caiazzo et al., 2011).  In addition to fibroblasts, astrocytes have 
also been efficiently converted into iDA by using a single polycistronic vector containing 
ASCL1, LMX1B and NURR1 (Addis et al., 2011). The fact that different somatic cells can be 
reprogrammed towards iDA using similar sets of transcription factors highlights their 
importance in reprogramming processes and reassigning cell fate. Reprogramming mouse 
fibroblast based only on Ascl1 and Pitx3 in another study resulted in immature iDA neurons 
after 4 weeks of culture (Kim et al., 2011b). However, inclusion of additional factors, such as 
En1, Foxa2, Lmx1a, and Nurr1, could fully reprogram fibroblasts into iDA neurons that were 
more similar at the molecular level to bona fide dopaminergic neurons (Kim et al., 2011b). 
Furthermore, the murine iDA neurons were able to alleviate symptoms in a mouse model of 
Parkinson’s disease, demonstrating their therapeutic potential for transplant therapies (Kim et 
al., 2011b). Although transdifferentiation of fibroblasts in the latter study could be achieved 
by ectopic overexpression of only 2 factors, the results suggested that additional factors are 
required to ensure proper maturation of the iDA neurons (Kim et al., 2011b). Furthermore, by 
adding SHH and FGF8 to the culture media, iDA neuron reprogramming could be enhanced 
up to 2 fold when using only 2 factors, and up to 3 fold when using the combination of 6 
factors (Kim et al., 2011b). These findings demonstrate that patterning molecules can act as 
critical enhancing components in promoting the generation of iDA neurons from fibroblasts. 
Notably, Theka et al. (2013) have established a fast protocol to obtain dopaminergic neurons 














mature and functional dopaminergic neurons in as few as 21 days, avoiding all the 
intermediate steps of induction and selection of EBs and NPCs. Strikingly, the resulting 
neuronal conversion process was very efficient, since approximately 93% of all the co-
infected iPSCs were forced to differentiate into postmitotic iDA neurons (Theka et al., 2013). 
The iPSC-derived neurons expressed all the critical molecular markers of midbrain 
dopaminergic neurons at the molecular level and exhibited sophisticated functional features, 
including spontaneous electrical activity and dopamine release (Theka et al., 2013). 
3.4 Induced GABAergic neurons 
In the first study that achieved to obtain iNs (Vierbuchen et al., 2010), some cells expressed 
markers of GABAergic differentiation (Vierbuchen and Wernig, 2011). However, whether 
enriched populations of induced GABAergic interneurons (iGNs) can be obtained has not 
been addressed until recently (See Table 2). Wasko (2013) was the first to demonstrate that 
mouse fibroblasts could be directly reprogrammed to iGN-like cells using different pools of 
transcription factors, including Dlx1, Dlx2, Lbx1, Lhx1, Lhx2, Pax2, Pitx2 and Pft1a in 
combination with members of the BAM factors. The author states that different groups 
containing these transcription factors have demonstrated some capacity for the derivation of 
iGNs, although the most efficient factor combination remains to be determined. Additional 
experiments will be required to fully characterize the efficiency of the different transcription 
factor pools, as well as to assess the functional properties and maturity of the eventual derived 
iGNs. Aside from fibroblasts, iGNs neurons have also been derived by overexpressing the 
ventral telencephalic fate determinant Dlx2 in murine astrocyte cultures (Heinrich et al., 
2010). Interestingly, they found that the overall efficiency of Dlx2-mediated neuronal 
reprogramming towards iGNs is much lower compared to Ngn2-mediated reprogramming 
towards induced glutamatergic neurons, suggesting that cortical astrocytes possess a higher 














addition, five different factors have been identified, including Ascl1, Bf1, Dlx6, Lhx6 and 
Sox2, which were able to convert mouse and human fibroblast, as well as human iPSCs, into 
iGNs that possessed characteristics of telencephalic GABAergic interneurons (Colasante et 
al., 2015). Molecular profiling showed pronounced activation of forebrain-specific 
(epi)genetic markers, required for GABAergic fate specification (Colasante et al., 2015). 
Furthermore, the iGNs displayed progressively maturing firing patterns comparable to cortical 
GABAergic interneurons, formed functional synapses, and released GABA upon stimulation 
(Colasante et al., 2015). The iGNs also survived and matured upon engraftment into the 
mouse hippocampus and optogenetic stimulation demonstrated functional integration of the 
grafted iGNs into the host circuitry, triggering inhibition of host granule neuron activity 
(Colasante et al., 2015). This latter study also elegantly demonstrated how human PSCs can 
be harnessed to generate GABAergic neurons. 
3.5 Induced serotonergic neurons 
There have only been two studies published that were able to directly obtain induced 
serotonergic (i5HT) neurons by transcription factor-mediated reprogramming of somatic cells 
(See Table 2). In the first study (Xu et al., 2015), human fibroblasts could be directly 
converted to i5HT neurons by the ectopic expression of ASCL1, FEV, FOXA2, and LMX1B. 
The transdifferentiation was enhanced by p53 knockdown and appropriate culture conditions, 
including hypoxia (Xu et al., 2015). Addition of the small-molecule compounds 
dorsomorphin (DOR), SB431542, ROCK inhibitor Y-27632 and the CDK4/6 inhibitor 
PD0332991 improved both the conversion efficiency and morphology of the obtained i5HT 
neurons, whereas addition of brain derived neurotrophic factor (BDNF) and glial derived 
neurotrophic factor (GDNF) slightly improved the morphology but not the conversion 
efficiency (Xu et al., 2015). The i5HT neurons expressed markers for mature serotonergic 














spontaneous action potentials, as well as spontaneous excitatory postsynaptic currents (Xu et 
al., 2015). Moreover, application of 5-HT significantly increased the firing rate of 
spontaneous action potentials (Xu et al., 2015). In the second study, it was demonstrated that 
overexpression of the transcription factors FEV, GATA2, LMX1B and NKX2-2 in combination 
with ASCL1 and NGN2 directly and efficiently generated i5HT neurons from human 
fibroblasts (Vadodaria et al., 2015). The i5HT neurons showed increased expression of 
specific serotonergic genes known to be expressed in the raphe nuclei, displayed spontaneous 
action potentials, released 5-HT in vitro and functionally responded to selective serotonin 
reuptake inhibitors (SSRIs) (Vadodaria et al., 2015).  
3.6 Induced cholinergic motor neurons 
Transcription factor mediated reprogramming has also been used to derive cholinergic motor 
neurons (See Table 2). Son et al. (2011) reported that the forced expression of the BAM 
factors, in combination with Hb9, Isl1, Lhx3 and Ngn2 was sufficient to convert mouse 
fibroblasts into induced motor neurons (iMNs). The iMNs were identified based on an 
HB9::GFP reporter and exhibited a morphology, gene expression signature, 
electrophysiological profile, synaptic functionality, in vivo engraftment capacity and 
sensitivity to degenerative stimuli, similar to ESC-derived cholinergic motor neurons (Son et 
al., 2011). By adding NEUROD1 to the 7 transcription factors they demonstrated that also 
human fibroblasts could be converted to iMNs (Son et al., 2011). Other studies have also 
coupled chemically defined systems with transcription factor-mediated reprogramming in 
PSCs in order to improve the efficiency and timing to obtain cholinergic motor neurons. For 
instance, adenoviral delivery of Isl1, Lhx3 and Ngn2 combined with exposure to RA and SHH 
signalling allowed rapid and efficient (>55%) acquisition of electrophysiological active 
human iMNs within 11 days (Hester et al., 2011). In a separate study, the same set of 














neuron identity (Mazzoni et al., 2013). Interestingly, replacement of Lhx3 by Phox2a led to 
specification of cranial, rather than spinal motor neurons, emphasizing the possibility to direct 
subtype specification. Phox2a and Phox2b have also been used to generate both visceral 
motor neurons and noradrenergic neurons from mouse ESCs in the presence of appropriate 
patterning molecules (Mong et al., 2014). Culturing Phox2b expressing cells under the 
signalling influence of FGF8 and BMPs promoted the generation of enriched noradrenergic 
cultures, while culturing Phox2a or Phox2b expressing cells with FGF8 and SHH generated 
cholinergic motor neurons instead (Mong et al., 2014). The authors demonstrated that the 
obtained neurons were suitable for drug testing in vitro and, therefore, harbour the potential 
for the discovery of therapeutic interventions. To conclude, these studies add up to the 
growing body of protocols, allowing to produce clinically relevant neuronal cells and 
demonstrate that combinations of distinct methods can work synergistically in obtaining the 
desired neuronal subtypes. 
4. Epigenetic-based approaches 
4.1 Epigenetics in directed differentiation and cellular reprogramming 
Even though every cell in the human brain shares an identical genotype, it consists of many 
neuronal subtypes with distinct, yet stable, profiles of gene expression patterns. As addressed 
above, this diverse repertoire of neurons is produced by extrinsic patterning cues and lineage-
specific transcription factors that define and reinforce these neuronal subtype-specific 
expression patterns. The neuronal phenotypes are further stabilized by the epigenetic 
machinery that maintains their genetic profile over a lifetime (Barrero et al., 2010; 
Vierbuchen et al., 2010). Epigenetics can be defined as stable and heritable modifications on 
the chromatin that occur without changes in the underlying DNA sequence (Delgado-Morales 
and Esteller, 2017). It is generally accepted that the epigenetic machinery includes multiple 














(Goldberg et al., 2007; Lardenoije et al., 2015). Histone modifications and DNA methylation 
are the most predominant examples of chromatin modifications that have been studied over 
the last years. Both of these modifications play an important role in neuronal cell fate 
determination and differentiation (Imamura et al., 2014). In continuously self-renewing ESCs, 
genes that regulate pluripotency are activated, whereas genes that regulate neuronal 
differentiation are repressed in a stable and heritable manner over many cell divisions 
(Avgustinova and Benitah, 2016; Coskun et al., 2012; Lilja et al., 2013; Olynik and Rastegar, 
2012). Moreover, this activation and repression needs to be inverted upon initiation of neural 
induction and differentiation. In addition to these chromatin modifications, noncoding RNAs 
are other important modulators that regulate gene expression patterns at the post-
transcriptional level (Lardenoije et al., 2015). A growing body of evidence is revealing that 
these also represent strong mediators of neuronal cell fate determination (Liu et al., 2012; 
Lukovic et al., 2014). Examples of noncoding RNAs include small interfering RNAs 
(siRNAs), small modulatory RNAs, ribosomal RNAs, transfer RNAs, natural antisense 
transcripts, enhancer RNAs and microRNAs (miRNAs), but many other subclasses have been 
described (Esteller, 2011; Guil and Esteller, 2012; Lardenoije et al., 2015). 
Based on the key role of the epigenetic machinery in assigning neuronal fate and identity, it 
has currently become evident that the underlying mechanisms of both directed differentiation 
and direct cellular reprogramming encompass epigenetic phenomena (Qin et al., 2016; Smith 
et al., 2016). A significant degree of transcriptional regulation takes place, where epigenetic 
mechanisms communicate with each other in collaboration with the extrinsic patterning cues 
and transcription factors to guide neuronal cell fate conversions. The profound epigenome 
remodelling processes in PSCs and somatic cells eventually lead to the acquisition and 
stabilization of neuronal subtype-specific gene expression profiles, which reinforce their 














differentiation along the neural lineage, please refer to Hirabayashi and Gotoh (2010), little is 
known about the extent in which these epigenetic mechanisms are identical in iPSC 
differentiation. The field is still in its infancy and we are just starting to understand 
similarities and differences in epigenetic and transcriptional states between iPSCs and ESCs 
(Huang and Wu, 2013; van den Hurk et al., 2016; Watanabe et al., 2013). In addition, the 
underlying epigenetic mechanisms of direct reprogramming in somatic cells are also still 
incompletely understood and the interactions between transcription factors and the chromatin 
architecture are currently under investigation (Firas et al., 2015; Qin et al., 2016). 
Nevertheless, considering the crucial role of chromatin modifications and transcriptional 
regulations by non-coding RNAs in modulating neuronal cell fate and identity, 
(re)programming and interfering with the epigenetic machinery offers an alternative approach 
for directing neuronal fates in vitro (See Figure 4, Table 3 and Table S3).   
4.2 Chemical compounds targeting chromatin-remodelling proteins 
First proof-of-concept on epigenetic-based approaches for neuronal differentiation in vitro 
came from experiments where beneficial effects on direct cellular reprogramming by 
chemical compounds that target chromatin-remodelling proteins were found (See Table 3). 
Genome-wide profiling of PSCs and their differentiated progeny has suggested a global, 
progressive transition from euchromatin to heterochromatin at various loci during 
differentiation (Chen and Dent, 2014). The epigenetic state of a differentiated cell is, 
therefore, considered to be more condensed and has significantly less dynamic exchange with 
transcriptional regulators (Chen and Dent, 2014). However, by targeting remodelling proteins, 
heterochromatin enriched regions can be altered and recruitment of transcriptional activators 
can be orchestrated to DNA sites that were previously inaccessible, allowing them to induce 
dramatic cell fate changes. As a consequence, epigenetic research in PSC differentiation and 














neuronal cell fate conversions. For instance, NPCs were induced from mouse fibroblasts by 
ectopic overexpression of Pax6 and Bf1 (Raciti et al., 2013). Treatment with a combination of 
small molecules that inhibit histone deacetylases (HDACs), H3K27 methyltransferases, and 
H3K4me2 demethylases accelerated the direct conversion of fibroblasts into NPCs up to ten 
times (Raciti et al., 2013). Remarkably, simultaneous inhibition of BMP- and TGF-β-
signalling almost doubled the frequency of NPCs, again demonstrating that combinations of 
different approaches can significantly enhance the derivation of the desired cell types in vitro. 
HDAC inhibitors and histone demethylase inhibitors coupled with other appropriate chemical 
patterning cues have also shown to turn mouse fibroblasts and astrocytes, as well as human 
urinary cells, into NPCs or neurons under physiological hypoxia conditions and without the 
need of additional transgene overexpression (Cheng et al., 2015a; Cheng et al., 2015b). 
Analysis of global gene expression patterns revealed a high degree of similarity between the 
induced NPCs and control NPCs (Cheng et al., 2015b), whereas the neurons induced from 
cultured astrocytes were electrophysiological active and expressed various subtype specific 
markers for dopaminergic neurons, GABAergic neurons, glutamatergic neurons and 
cholinergic motor neurons (Cheng et al., 2015a). The delivery of small molecules or 
systematic administration of drug cocktails enabling astrocytic-to-neuronal conversions bear 
the potential for direct induction of desirable cells from resident astrocytes in situ, while 
bypassing possible adverse effects of genome integrating constructs. Taken together, drugs 
targeting the chromatin can improve reprogramming efficiency and might function as useful 
adjuvants in currently used reprogramming protocols, thereby providing a possible alternative 
strategy to produce patient-specific neuronal cells.  
4.3 Epigenetic editing 
Epigenetic editing systems (Kungulovski and Jeltsch, 2016; Thakore et al., 2016) offer an 














used directed differentiation and cellular reprogramming protocols (Jurkowski et al., 2015). 
Making locus-specific alterations to the epigenetic code allows to (re)shape the mechanistic 
relationships among chromatin state, gene regulation, and cellular phenotype by the natural 
dynamics of gene expression (Thakore et al., 2016). For this reason, these epigenetic editing 
systems allow probing of signatures responsible for cellular identity and provide intelligent 
control to direct neuronal cell fates in PSCs and somatic cells (Black et al., 2016; Chavez et 
al., 2015; Kearns et al., 2014; Victor et al., 2014). DNA-targeting platforms based on the 
initially established zinc finger proteins (ZFPs), transcription activator-like effector nucleases 
(TALENs) and the clustered, regularly interspaced, short palindromic repeats (CRISPR)-Cas9 
systems, have allowed the recruitment of transcriptional modulators and epigenome-
modifying factors to any genomic locus (Kungulovski and Jeltsch, 2016; Laufer and Singh, 
2015; Thakore et al., 2016). Virtually any DNA sequence can be targeted with these 
customizable synthetic epigenetic tools (Thakore et al., 2016). The direct fusion of 
transcriptional effector domains to designed DNA-targeting domains can induce 
transcriptional activation or repression of endogenous key-lineage-determinant genes 
(Thakore et al., 2016). Transcriptional effector domains include epigenetic effectors that 
directly catalyse covalent modifications to DNA or histones, or that recruit other histone 
modifying enzymes, as well as interfere with chromatin-binding proteins. For instance, 
epigenetic effectors that directly catalyse covalent modifications to DNA, such as DNA 
methyltransferases (DNMTs) or ten-eleven translocation (TET) enzymes, can methylate or 
demethylate CpGs at non-neuronal and neuronal target promoters, leading to transcriptional 
repression or induction, respectively (Jurkowski et al., 2015; Liu et al., 2016). Other effector 
domains such as VP64 can recruit histone remodelling factors, leading to increased chromatin 
accessibility and to the deposition of activating histone modifications at desired neuronal loci 














domains without an epigenetic effector to promoter regions or regions downstream of the 
transcription start sites can silence non-neuronal gene expression by steric hindrance of 
lineage-specific transcription factor binding and RNA polymerase elongation (Chavez et al., 
2015; Jurkowski et al., 2015). Thus, custom epigenetic and transcriptional regulation by 
epigenetic editing-based approaches offer refined control over cell fate decisions, providing 
an invaluable tool for applications such as directed differentiation and cellular reprogramming 
along the neural lineage (See Table 3). 
Several pioneer studies utilizing these epigenetic editing systems have shown successful and 
precise deposition or removal of different chromatin modifications to induce directed 
differentiation and cellular reprogramming for multiple cell types, including iPSCs, myocytes 
and neurons. Gao et al. (2013) used TALE-based transactivators targeting distal enhancers of 
Oct4 in concert with Sox2, Klf4 and Myc transgene overexpression to generate mouse iPSCs. 
More recently, a protocol for the direct conversion of mouse fibroblasts to skeletal myocytes 
using a dCas9-based transactivator targeting the endogenous Myod1 gene has been developed 
(Chakraborty et al., 2014). Other groups have also applied dCas9-based transcriptional 
regulation to direct the differentiation of human PSCs (Balboa et al., 2015; Chavez et al., 
2015). In an elegant study, human iPSCs were derived from human skin fibroblast by 
replacing OCT4 overexpression with dCas9-mediated activation of the endogenous promoter 
(Balboa et al., 2015). The authors demonstrated that directed endodermal differentiation of 
the iPSCs could be achieved by targeting proximal promoters of endodermal and pancreatic 
key-regulatory transcription factors, including FOXA2, SOX17, GATA4, PDX1, and NKX6-1 
(Balboa et al., 2015). Directed neuronal reprogramming through multiplex endogenous gene 
activation using an engineered VP64-dCas9-VP64-based transcriptional activator has also 
been achieved (Black et al., 2016). Induced activation of the BAM factors successfully 














later stages of reprogramming despite the transient delivery of the guide RNAs (gRNAs) 
(Black et al., 2016). In a separate study, it was demonstrated that rapid and robust neuronal 
differentiation of human iPSCs could be achieved by targeting NGN2 and NEUROD1 with a 
VP64-p65-Rta-dCas9-mediated transcriptional activator (Chavez et al., 2015). Although 
many of the aforementioned reports include targeted activation of a single gene in 
combination of concurrent overexpression of multiple transcription factors, these latter 
examples also demonstrate that multiplex activation with a collection of gRNAs against a set 
of genes can be used to direct somatic cell reprogramming.  
Previous studies have demonstrated that targeted epigenetic editing of the regulatory elements 
controlling expression of lineage-specific transcription factors is sufficient for direct 
conversion between cell types, emphasizing the feasibility and potential advantages of using 
these synthetic epigenetic systems to direct neuronal cell fate of PSCs and somatic cells in 
vitro. Moreover, epigenetic editing in isolation has incredible promise as a platform for 
disease modelling both in vitro, as well as in vivo, whereas using it for transdifferentiation 
within the native physiological niche of the human brain might provide an alternative strategy 
to achieve cell fate conversions for applications in regenerative medicine (Cano-Rodriguez 
and Rots, 2016; Fu et al., 2014a; Liu et al., 2016). Several labs have recently pioneered in 
vivo reprogramming in the brain and spinal cord by converting endogenous glial cells (Gascón 
et al., 2016; Guo et al., 2014; Torper et al., 2013) and NPCs (Niu et al., 2013; Ohori et al., 
2006) into functional neurons. For a more in-depth review on more surpassed studies, please 
refer to Li and Chen (2016) and Srivastava and DeWitt (2016). Epigenetic editing systems 
applied in a safe and efficient manner that target similar lineage-specific transcription factors, 
might allow to induce any desirable neuronal subtype in vivo and could eliminate undesired 
issues in cell transplantations that may arise due to precedent in vitro cultures. To conclude, 














context of inducing neuronal phenotypes and bear excessive potential for many different 
applications in fundamental research and biomedicine. 
4.4 RNA interference using miRNAs 
On the one hand, the acquisition of distinct histone and DNA modifications at neuronal genes 
and non-neuronal genes plays a role in determining neuronal identity. On the other hand, 
neuronal identity is also determined by synergistic actions of extrinsic cues and the combined 
expression of transcription factors that are modulated by transcriptional regulators, including 
non-coding RNAs. Among these, miRNAs have been most extensively studied in relation to 
cellular identity and although most of the other subclasses are also anticipated to play 
important roles in regulating neuronal cell fate determination, the exact contribution of many 
remains elusive. Currently, it is accepted that miRNAs promote the transition from ESC self-
renewal to differentiation by either directly suppressing the self-renewal state or by stabilizing 
the differentiated state (Ong et al., 2015). In addition, multiple miRNAs target components or 
modulators of neural developmental signalling pathways, such as BMP and TGF-β signalling, 
and have been identified to either positively or negatively affect entry along the neural lineage 
(Stappert et al., 2015). In mature neurons, it has been proposed that the cellular miRNA 
milieu might even be unique in each subtype and required to facilitate developmental 
transitions during differentiation (Lopez-Ramirez and Nicoli, 2014). Some miRNAs even 
exhibit region-specific expression patterns in the brain, suggesting that neuronal subtypes 
residing in these regions may express different miRNA profiles (Stappert et al., 2015). This is 
exemplified by a study of He et al. (2012), in which they demonstrated substantial differences 
between the miRNA repertoire expressed in glutamatergic neurons and GABAergic 
interneurons that co-expressed either PV or SST. Specifically, miR-133b and miR-187 were 














neurons, where miR-133b was more abundant in PV expressing and miR-187 in SST 
expressing GABAergic interneurons (He et al., 2012).  
Based on the emerging role of miRNAs during neural induction, neuronal differentiation and 
neuronal subtype specification, techniques such as RNAi using miRNAs holds great promise 
as an alternative tool to direct neuronal cell fate in vitro (See Table 3) (Low et al., 2012; 
Stappert et al., 2013). RNAi is a post-transcriptional gene silencing technique that has 
therapeutic opportunities for the treatment of various human disorders and has extensively 
been employed in translational studies to address fundamental biological questions (Low et 
al., 2012). The potential of RNAi lies in its capacity to virtually target any RNA molecule of 
interest, which allows fine-tuning of expression of key-determinant factors in neuronal fate 
determination. Approaches to downregulate endogenous miRNA expression to influence gene 
expression opposite of RNAi are also available and could for example be achieved by using 
anti-sense oligonucleotides (ASOs) (See Table 3) (Davis et al., 2006). The temporal control 
of miRNA regulation might facilitate the induction of neuronal subtype-specific 
transcriptional networks and aids in recapitulating the natural dynamics of transcriptional 
regulation during neuronal cell fate commitment. Each miRNA has multiple molecular targets 
that might play essential roles in the derivation of specific neuronal subtypes and modulating 
a single miRNA could, therefore, guide entire neural developmental processes. Moreover, 
successful delivery of miRNAs could be achieved in many different ways depending on the 
needs of the experiments, as each method has different transfection efficiencies and transgene 
expression duration. Representative methods that allow expression of a miRNA construct 
include non-viral delivery systems such as lipid-based transfection, electroporation or the use 
of microvesicles, or viral delivery systems such as lentiviruses and adeno-associated viruses 














The potential of miRNAs to complement current practiced directed neuronal differentiation 
protocols from PSCs was first demonstrated by Kim et al. (2007). Interestingly, in this study 
they reported an unexpected negative impact of miR-133b on the generation of dopaminergic 
neurons from mouse ESCs. MiR-133b was found to be enriched in the human midbrain, while 
overexpression in this study impaired the generation of TH-positive cells (Kim et al., 2007). 
Inhibition of miR-133b on the other hand, resulted in an increased dopaminergic 
differentiation. The authors speculated that miR-133b regulates the maturation and function of 
midbrain dopaminergic neurons within a negative feedback circuit that includes the 
dopaminergic transcription factor Pitx3. A similar negative impact on the differentiation of 
dopaminergic neurons from mouse ESCs has been reported in a separate study (Yang et al., 
2012). Inhibition of miR-132 promoted the differentiation of dopaminergic neurons, while 
ectopic expression of miR-132 decreased the derivation of TH-positive cells without affecting 
the total number of neuronal cells. Through a bioinformatics assay they identified Nurr1 as a 
potential molecular target of miR-132, which also represents a key transcription factor of 
dopaminergic neuron specification. Stappert et al. (2013) showed that miR-125b and miR-
181a specifically promote the generation of neurons of dopaminergic fate from NPCs derived 
from human ESCs, whereas miR-181a* inhibits the development of this neurotransmitter 
subtype. By using a set of miRNA-mimics and –inhibitors, they also demonstrated that 
inhibition of miRNA-124 enhances the development of dopaminergic neurons (Stappert et al. 
2013). Although other studies on additional neuronal subtypes have not been published, these 
studies demonstrated that time-controlled modulation of specific miRNA activities can 
contribute to the derivation of defined neuronal cells in vitro. 
Recent developments in direct somatic cell reprogramming also highlighted the potential of 
miRNAs as mediators for transdifferentiation along the neural lineage. The convergence of 














miR-9/9* and miR-124, which both belong to a set of brain-enriched miRNAs that are 
activated upon initiation of neurogenesis (Abernathy et al., 2017). It has been shown that 
overexpression of miR-124 along with BRN2 and MYT1L is able to reprogram human 
fibroblasts into functional neurons in the absence of other cell types (Ambasudhan et al., 
2011). These iNs exhibited typical neuronal morphology, appropriate electrophysiological 
properties and were able to form functional synapses between each other (Ambasudhan et al., 
2011). In a separate study, it was reported that the expression of miR-9/9* and miR-124 in 
human fibroblasts induced their direct conversion into neurons, a process which was enhanced 
by the addition of several transcription factors, including ASCL1, MYT1L and NEUROD2 
(Yoo et al., 2011). Importantly, they found that the expression of these transcription factors 
alone without the miRNAs was inefficient to induce a neuronal phenotype, suggesting that 
this miRNA-induced neuronal state is indulgent to subtype-specific transcription factors that 
can initiate and advance differentiation towards mature neuronal identities (Abernathy et al., 
2017). Co-expression of miR-9/9* and miR-124 with transcription factors enriched in the 
developing striatum, including CTIP2, DLX1, DLX2, and MYT1L, guided the conversion of 
human fibroblasts into enriched populations of GABAergic neurons analogous to striatal 
medium spiny neurons (Victor et al., 2014).  
Synergism between miR-9/9*, miR-124 and two other neuronal subtype-specific transcription 
factors, i.e. ISL1 and LHX3, has also been shown to be able to induce a highly homogeneous 
population of spinal cord motor neurons in adult human fibroblasts (Abernathy et al., 2017). 
Longitudinal analyses of the transcriptome, genome-wide DNA-methylation, and chromatin 
accessibilities in the latter study revealed that miR-9/9* and miR-124 trigger reconfiguration 
of the epigenome, including activation of a pan-neuronal program and the reconfiguration of 
chromatin accessibilities (Abernathy et al., 2017). Neurons solely induced by miR-9/9*- and 














subtypes, but possess open chromatin structures at neuronal subtype-specific loci that can be 
activated upon further instructions (Abernathy et al., 2017). The authors, therefore, also 
suggested that expression of bot miRNAs in somatic cells initiates gradual but active changes 
in the activities of multiple chromatin modifiers while simultaneously repressing anti-
neuronal genes and activating neuronal genes, resulting in the binary cell fate switch. The fact 
that pre-existing neuronal loci within the heterochromatic regions opened-up in response to 
miR-9/9* and miR-124, suggests that miRNA-mediated reprogramming could indeed stem 
from their ability to induce remodelling of the epigenome. Taken together, these findings 
demonstrate that miR-9/9* and miR-124 control the neurogenic potential of somatic cells and 
provide a platform for the foundation of subtype-specific neuronal conversions of human 
cells. For a further in depth description of all other brain-enriched miRNAs, their target genes 
and exact functions, please refer to excellent reviews by Åkerblom and Jakobsson (2014), 
Coolen et al. (2013), Meza-Sosa et al. (2014) and Stappert et al. (2015).  
To conclude, miRNA-mediated neuronal differentiation and transdifferentiation have enlarged 
our current toolkit for directing neuronal cell fate in vitro and have the potential to widen our 
understanding on the transcriptional regulations in cell fate decisions. Further insights could 
in the end be exploited to develop new protocols in order to obtain enriched populations of the 
complete repertoire of neurons found in the human brain. 
5. Discussion and future directions 
The establishment of efficient stepwise protocols to obtain functional neurons in vitro is 
highly essential for the study of human brain functions, as well as disease modelling, drugs 
discovery and regenerative medicine. In this review, we have highlighted the advances that 
have been made over the last two decades in obtaining neuronal cells from PSCs and somatic 
cells. Insights from basic research and developmental biology have guided the design of 














serotonergic, and cholinergic/motor neurons have become available. The use of chemically 
defined systems and ectopic overexpression of key lineage-specific transcription factors have 
been first-choice to direct neuronal fates in vitro. In the chemically defined systems, PSCs 
have been exposed to a variety of cocktails containing patterning cues and small molecules 
that induce differentiation towards early NPCs and eventually specific mature neuronal 
subtypes. Classical experiments such as nuclear transfer or cell fusion on the other hand, have 
demonstrated that differentiated cells are not irreversibly committed to their fate. Very recent 
work has built on these conclusions and discovered that ectopic overexpression of defined 
transcription factors can directly generate iNs from distinct somatic cell types, as well as from 
PSCs. Other groups have combined both approaches and have shown successful derivation of 
neuronal populations and increased protocol efficiencies in both PSCs and somatic cells.  
Scientists have also uncovered the existence of intrinsic mechanisms that influence the 
responsiveness to patterning cues and transcription factors. As we have outlined above, recent 
work has demonstrated a significant contribution of the epigenetic machinery to assigning 
neuronal fate and identity. From cancer studies, it is also becoming apparent that shifts in 
epigenetic signatures underlie phenotypic changes, and can induce stem cell-like properties in 
cancer cells due to transcriptional reprogramming (Mateo et al., 2017). Several pioneering 
studies have now used this knowledge in combination with the current growing availability of 
epigenetic editing systems and RNAi, enabling the modification of epigenetic marks at key-
determinant loci that allow to direct neuronal fates in vitro. Additionally, lists of potential 
drugs and drug targets such as histone-modifying enzymes have been suggested to improve 
neuronal conversions. Such approaches on their own or in combination with others could lead 
to an accelerated application of the obtained neuronal populations. It is therefore, anticipated 
that epigenetic editing systems and RNAi will be increasingly involved in PSC-differentiation 














potential to become a golden standard for probing interactions among specific chromatin 
modifications, transcriptional programmes and cellular phenotypes. However, care should be 
taken in terms of advantages and disadvantages that come together with each of the 
aforementioned methods. For instance, off-target effects with the use of epigenetic-based 
strategies are common and should be reduced at all times to prevent experimental bias and 
undesirable outcomes, especially when one would consider the use of these cells in 
regenerative medicine. Such systems in combination with genome-integrating techniques can 
affect the genome in a way that it might lead to adverse changes in the biology of the cell, 
including changes in its differentiation potential. Genome-integrating constructs are randomly 
incorporated into the host genome and the copy number of the exogenous DNA per cell may 
vary to great extent, since there are often no specific genetic elements or no apparent logic for 
their integration (Medvedev et al., 2010). Furthermore, integration can occur into various 
chromatin-regulatory elements and interfere with gene-coding sequences, possibly affecting 
endogenous transcriptional regulation and three-dimensional chromatin structures. Finally, 
there is a possibility that transgenes maintain their activity or reactivate in the progeny of the 
initial targeted cell type. Nevertheless, studies have already shown to circumvent the issue 
with genomic-integrating techniques by the use of removable constructs, non-integrating 
systems such as adeno-associated vectors, transfections of mRNAs, transduction of 
reprogramming proteins and the use of small molecule compounds. Furthermore, promoters 
controlled by chemical compounds that allow to regulate transgene transcription, such as 
doxycycline (DOX) for example (See Table 2 and Table 3), might provide an alternative to 
prevent continuously expressed transgenes and, thus, allows better temporal control of 
transgene activation.  
Despite the achievements in directing neuronal cell fate in vitro, several other challenges also 














be utilized. Different cultivation protocols for each neuronal subtype currently exist and the 
majority of these protocols result in heterogeneous neuronal populations with remarkable 
differences in efficiency. Furthermore, we are currently also unable to enrich for the full 
repertoire of neurons found in the human brain, especially when considering specific 
anatomical subtypes within neurotransmitter classes. For these reasons, the refinement and the 
search for alternative approaches that will allow us to obtain all known neuronal subtypes 
found in the human brain remains an ongoing demand. Although multicellular cultures will be 
pivotal for brain-related studies, optimizing the used parameters and devising strategies to 
enrich for specific neuronal subtypes will also be essential in order to obtain pure populations 
of neurons, which will allow mechanistic studies and clinical applications in which 
confounding effects from other cell types can be kept to a minimum. In this respect, one could 
think of combining different protocols or adding additional factors to existing protocols that 
may act synergistically in mimicking the complete molecular processes that (re)assign cell 
fates along the neural lineage. As has been shown in many available approaches, every single 
driving factor fulfils a crucial role as a part of a bigger network and absence of a single 
component can completely redirect the terminal differentiation, as well as induce incomplete 
differentiation or reprogramming processes, leading to the production of immature cells that 
may not fully recapitulate bona fide neurons. By combining directed differentiation with 
transcriptional reprogramming and/or epigenetic-based approaches, one might be able to 
control these cellular conversions in a robust way, which could, in turn, also lead to a greater 
diversity of neuronal subtypes to be specified in vitro. Another option to enhance culture 
purity could be achieved by finding more effective ways to isolate the desired cell types in 
different developmental stages. The use of specific cellular markers or expressing constructs 
combined with cell-sorting techniques, such as fluorescence-activated cell sorting (FACS) and 














The choice of the initial tissue and cell type for generating the neuronal populations also 
needs considerable attention and could significantly affect the efficiency of a neuronal 
differentiation protocol. For instance, it is currently recognized that there are epigenetic 
differences between different PSC lines that can induce lineage differentiation bias 
(Nishizawa et al., 2016). This is exemplified in the study by Kim et al. (2011c), where they 
observed that the majority of neurons generated from one iPSC line were glutamatergic, 
whereas populations generated from another iPSC line mainly consisted of GABAergic 
neurons, when exposed to the same chemical culture conditions. Scientists have committed to 
the challenge to find markers that will allow them to predict this bias. The presence of such a 
marker could reveal which cell line has the highest neuronal differentiation capacity, leading 
to an increased neuronal conversion efficiency later on. It is noted that the origin-dependent 
epigenetic and transcriptional patterns of the pluripotent state can render iPSC lines with 
different neuronal differentiation potential. Cell lines that harbour epigenetic signatures, 
which were maintained and are characteristic of the somatic tissue of origin, have been shown 
to favour differentiation along lineages related to the donor cell, while restricting alternative 
cell fates (Kim et al., 2010). Furthermore, it has been show that expression levels of other 
transcriptional regulators in iPSCs, such as miR-371-3, can predict neuronal differentiation 
propensities (Kim et al., 2011a). Aside from presenting the concept of epigenetic memory that 
may influence efforts in directed differentiation in iPSCs, this also emphasizes the role of 
epigenetic mechanisms in neuronal differentiation and addresses the complexity of the 
neuronal fate determination that needs the warrant for more comprehensive comparisons 
between different PSC lines.  
Another debate in relation to starting cell choice, but based on direct reprogramming, arises 
from the initial assumption that developmentally related cells convey a higher conversion 














2016). Indeed, previous studies have shown that cells derived from the same lineage, such as 
astrocytes and neurons, can be converted with minimal sets of transcription factors, whereas 
cells of non-ectodermal origin require more than one factor or additional chemical stimulation 
(Gascón et al., 2017). Even though this is not always the case, as conversion of one neuronal 
subtype into another is rather difficult and has been achieved only in immature cells (Gascón 
et al., 2017; Rouaux and Arlotta, 2013), lineage boundaries established during cellular 
differentiation and specification might be overcome, depending on the potency of the factors 
that are employed (Masserdotti et al., 2016). However, the questions to what extent direct 
reprogramming recapitulates the natural dynamics of neuronal differentiation and whether the 
developmental origin and, more specifically, the epigenetic memory of the starting cell type is 
negligible when using the proper reprogramming factors remain unanswered. The underlying 
principle of direct reprogramming is based on the expression of key lineage-specific 
transcription factors that are essential during development, but their action during direct 
reprogramming can be rather different, since these factors are operating in a completely 
different context (Masserdotti et al., 2016). Further studies on how factors function in various 
reprogramming environments may bring new insight that can lead into the establishment of 
more robust neuronal differentiation protocols in various somatic cell subtypes, as well as in 
PSCs. Additionally, detailed characterization of the cellular and molecular characteristics 
involved in guiding PSC-differentiation and somatic cell reprogramming along the neural 
lineage is expected to contribute, not only to enhance our understanding on the developmental 
aspects, but also to develop more efficient protocols and rational interventions (Kee et al., 
2017; Kirkeby et al., 2017). Continuous characterization of patterning cues, small molecules 
and other driving factors, as well as a comprehensive understanding of the underlying 
molecular pathways that they target will be necessary to achieve a higher efficiency, decrease 














direct comparison of differentiated cells versus undifferentiated counterparts will be crucial in 
order to find signalling mechanisms, as well as to develop a comprehensive understanding of 
the epigenetic state and transcriptional programmes involved in neuronal fate specification. 
Such knowledge can in the end be exploited to manipulate single molecules or even complete 
molecular networks in the developmental processes and, hence, could aid the production of 
specific neuronal cells of interest. With the current advances of next-generation sequencing 
technology we are now also able to define genome-wide expression patterns and epigenetic 
modifications in each cell type. Such approaches have already demonstrated that different 
cellular subtypes display unique epigenetic signatures that persist as ESCs differentiate into 
the neuronal lineage. However, how these unique signatures are acquired in specific gene 
promoters or to what extent they are involved in shaping neuronal fates remains to be 
elucidated. 
A final point of consideration with regard to the use of PSC- and somatic cell-derived 
neuronal populations in fundamental research and biomedicine, is that the conventional cell 
culture systems do not fully resemble the in vivo cellular microenvironment, where three-
dimensional cell-to-cell interactions form the foundation of the human brain. The simplicity 
of an in vitro culture system is an advantage, as well as a significant disadvantage, when 
cellular homogeneity becomes a reliability. Studying pure populations of neuronal subtypes 
that are in principle part of a more complex integrated cellular network, might lead to under- 
or overrepresentation of experimental findings depending on the research question. Organoids 
or three-dimensional culture systems in combination with bioprinting might offer a way to 
circumvent this issue (Fatehullah et al., 2016; Lancaster and Knoblich, 2014; Murphy and 
Atala, 2014). Several studies have already succeeded in establishing organoids that imitate 
many features of human cortical development in a precise and complex manner (Dezonne et 














iPSCs hold great potential for the investigation of developmental and evolutionary features of 
the human brain and provides a useful platform for drug screening and disease modelling 
(Dezonne et al., 2017; Nascimento and Martins-de-Souza, 2015). Additionally, the 
technology of decellularization and recellularization on obtained tissue matrixes to create 
entire organs in vitro is currently also under development (Fu et al., 2014b). Unfortunately, 
despite these advances, the challenge of how to generate organs that cherish the highly 
integrated cellular complexities like in the human brain persists, and will require collaborative 
multidisciplinary expertise to overcome. Nevertheless, neuronal in vitro differentiation 
techniques in combination with these advanced three-dimensional culture systems represent 
powerful tools for future brain-related studies. The potential to manipulate (epi)genetic and 
environmental factors in culture conditions, with the possibility to characterize cellular 
functions, electrophysiological properties and cellular connectivity of various neuronal 
subtypes in isolation, as well as organized in a multi-layered dimension, will be of great utility 
to enhance our current understanding on brain disorders and will undoubtedly contribute to 
the development of therapeutic interventions. 
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Figure 1. Overview of methods and applications for neurons obtained by directed 
differentiation and (direct) cellular reprogramming in embryonic stem cells (ESCs), induced 
pluripotent stem cells (iPSCs) and somatic cells. (A) The figure shows the complete directed 
differentiation and (direct) cellular reprogramming toolkit currently available, including the 
use of patterning factors, chemical compounds, small molecules, transcription factors, 
epigenetic editing and RNA interference (RNAi) with the use of microRNAs (miRNAs) as 
example. The neurodevelopmental transitions starting from PSCs towards neural precursor 
cells (NPCs) and eventually mature neurons are depicted. Directed differentiation protocols 
can generally be divided into three methods: monolayer methods, co-culture methods and 
embryoid body (EB) methods. Reprogramming of somatic cells towards iPSCs can be 
achieved by increased expression of transcription factors, such as Oct3/4, Sox2, Klf4 and Myc 
(OSKM, Yamanaka factors). Direct reprogramming of somatic cells towards specific 
neuronal subtypes can be achieved by co-expression of the pan-neuronal factors Brn2, Ascl1, 
Myt1 (BAM) and Neurod1 among others, and neuronal subtype-specific transcription factors. 
(B) The direct applications of the obtained neurons in fundamental research and biomedicine, 
including the use for disease modelling, drug discovery and regenerative medicine, are shown. 
Figure 2. Schematic overview of the working mechanisms of chemically defined neuronal 
differentiation systems and the underlying neurodevelopmental principles that they 
recapitulate in vitro. (A) The figure shows how various morphogen signalling gradients, 
including bone morphogenic protein (BMP), wingless-type MMTV integration site family 
(WNT), fibroblast growth factor (FGF), sonic hedgehog (SHH) and retinoic acid (RA), as 
well as inhibitors/antagonists (α) of these pathways, pattern the various brain regions during 
early embryonic development both along the rostral-caudal and dorsal-ventral axes. The 
depicted brain regions include the telencephalon (TEL), diencephalon (DI), mesencephalon 














same chemical patterning principles as seen in vivo, pluripotent stem cells (PSCs) and neural 
precursor cells (NPCs) can be patterned towards neuronal subtypes in vitro, corresponding to 
the brain regions where they typically originate from.   
Figure 3. Schematic overview of the working mechanisms of transcription factor-mediated 
reprogramming along the neural lineage in vitro. (A) The figure shows how embryonic stem 
cells (ESCs), induced pluripotent stem cells (PSCs) and somatic cells can be reprogrammed 
towards neurons by transcription factor-mediated fate instructions. (B) The initial active (in 
green) transcriptional network that defines and reinforces cellular identity can be perturbed by 
induction of exogenous key-lineage determinant factors (in blue), leading to the activation (in 
green) of the neuronal transcription factor network and deactivation (in red) of the initial 
cellular network, which underlies the cellular fate switch. 
Figure 4. Schematic overview of the working mechanisms of epigenetic-based approaches for 
neuronal differentiation in vitro. (A) The figure shows how somatic cells, pluripotent stem 
cells (PSCs) and neural precursor cells (NPCs) can be differentiated or reprogrammed into 
neurons. (B) In each of these cells, histone and DNA modifications orchestrate transcriptional 
activity of pluripotency genes, self-renewal genes, neuronal genes and somatic genes, which 
define their cellular identity. While somatic genes are only active in somatic cells (in green), 
genes that regulate pluripotency and self-renewal are activated in PSCs (in green), whereas 
genes that regulate neuronal differentiation are repressed and poised (in red with green 
modifications) for activation upon further developmental cues. This activation and repression 
is inverted upon initiation of neural induction and differentiation, leading to the activation of 
neuronal genes (in green) and repression of PSC genes (in red). By using epigenetic editing 
and molecules that allow modifying the chromatin structure, activity of genes that redefine 
and reinforce cellular identity can be altered, offering control over neuronal fate determination 














modifications, it has been proposed that the cellular microRNA (miRNA) milieu is unique in 
each cellular subtype and required to facilitate developmental transitions during neuronal 
differentiation. For PSC regulation, miRNAs such as miR-371 and miR-302 are important, 
while miR-9/9* and miR-124 belong to brain-enriched miRNAs that are activated during 
neuronal specification. By using RNA interference (RNAi), miRNA profiles that redefine and 
reinforce cellular identity can be manipulated, leading to changes in transcriptional regulation 






























































Table 1. Chemically defined differentiation systems for neural induction and differentiation 
in vitro per neuronal phenotype. 












ESCs EB RA 
±85% TUJ1+ 
93 ± 4.7% VGLUT1+/TUJ1+ 
















DKK1, Lefty-1 and 
SB431542 
Mouse 




ESCs EB None 
±79% TBR1+/TUJ1+ 
±57% CTIP2+ 













ESCs and iPSCs (Spin) EB 
DOR, DKK1, EGF, 
FGF2 and NOG 
iPSCs (8011) 
Kim et al. (2011c) 
94.7 ± 2.5% VGLUT1+/MAP2+ 















32.8 ± 8.1% VGLUT1+/MAP2+ 























FGF2, FGF8 and 
SHH 
±68% GABA+/TUJ1+ 





FGF2, NOG and 
SHH-C25II 
91.6 ± 4.4% BF1+/Lxh6-GFP+ 
70.5 ± 7.7% DLX2+/Lxh6-GFP+ 
97.7 ± 3.1% LHX6+/Lxh6-GFP+ 
94.6 ± 3.7% GABA+/Lxh6-GFP+ 










Watanabe et al. 
(2005) 
Human 
ESCs EB DKK1 and SHH ±84% NKX2-1+ Li et al. (2009) 
ESCs and iPSCs EB 
SHH-C24II, SHH-






















DKK1, DOR, NOG, 
SHH-C25II and 
SB431542 
ESC and iPSCs 
Carri et al. (2013) 
±58% BF1+ 












DKK1, PUR and 
SB431542 
ESCs 
Nicholas et al. 
(2013) 
74.9% ± 2.1% NKX2-1-GFP+ 
81.5 ± 3.6% BF1+/NKX2-1-GFP+ 
75.8 ± 2.3% GABA+/NKX2-1-GFP+ 





































EGF, FGF2 and 
VPA1 
68 ± 4% MAP2+ 
90% GABA+/MAP2+ 
54% CALB1+/MAP2+ 
Lin et al. (2015) 
DKK1, EGF, FGF2 
and SHH 
63 ± 4% MAP2+ 
96% GABA+/MAP2+ 
84% CALB1+/MAP2+ 






FGF2, FGF8 and 
SHH 
50 ± 10% TH+/TUJ1+ 





52 ± 9% TUJ1+ 
30 ± 4% TH+/TUJ1+ 
Kawasaki et al. 
(2000) 
EB 
FGF2, FGF8 and 
SHH 
71.9 ± 6.9% TUJ1+ 
33.9 ± 5.5% TH+/TUJ1+ 








52.5 ± 2.56% TUJ1+ 
38.2 ± 2.15% TH+ 
75.0 ± 3.02% TUJ1+/TH+ 







After in vivo transplantations 
Kirkeby et al. 
(2012) 
54.2 ± 2.5% TH+ 
81% LMX1A+/FOXA2+ 
EB 
FGF2, FGF8 and 
SHH 
50-60% TH+/TUJ1+ Yan et al. (2005) 
iPSCs EB 
FGF2, FGF8 and 
SHH 
30 ± 5% TH+ 
±100% GIRK2+/TH+ 
Swistowski et al. 
(2010) 
FGF2 6.5 ± 1.4% TH+ Cai et al. (2010) 
                                                          





















42 ± 4.4% TH+ 
19.9% ± 6.9% NURR1+ 
70%–75% FOXA2+ 
Doi et al. (2014) 








PUR, SB431542 and 
SHH-C25II 
ESCs 



















Human ESCs and iPSCs 
Xi et al. (2012) 
43.6 ± 6.2% TH+ 
95.3 ± 2.4% NURR1+/TH+ 
96.7 ± 1.8% FOXA2+/TH+ 
96.5 ± 2.3% LMX1A+/TH+ 







FGF2, FGF4 and 
SHH 
±57% 5-HT+/TUJ1+ 
Barberi et al. 
(2003) 
EB 
FGF2, FGF8 and 
SHH 






Shimada et al. 
(2012) 
±6% 5-HT+/TUJ1+ 
Human ESCs EB 
5-HT, FGF2, 
FGF10, Forskolin 
and  RA 
±20% TUJ1+ 
<69 ± 4% 5-HT+/TUJ1+ 
40% TPH+/MAP2+ 
40 ± 4% MAP2+/5-HT+ 






























Vadodaria et al. 
(2015) 
ESCs and iPSCs Monolayer 
CHIR99021, DMH-
1, FGF4, SB431542 
and SHH-C25II 
ESCs and iPSCs 








FGF2, RA and SHH ±60% HB9+/TUJ1+ 
Barberi et al. 
(2003) 
ESCs (Hb9::GFP) EB 
Hh-Ag1.3, RA and 
SHH 
25% ± 5% HB9+ 
25% ± 5% HB9-GFP+ 
>70% ISL1+/ HB9+ 
Wichterle et al. 
(2002) 
Human 




Li et al. (2005) 
ESCs 
(Hb9::EGFP) 
EB RA and SHH 
35.3 ± 24.9 TUJ1+ 
56.1 ± 9.9% ISL1+/CHAT+/TUJ1+ 
37.4 ± 3.3% HB9+/TUJ1+ 
96.3 ± 12.5% HB9+/Hb9-GFP+ 
88.7 ± 7.4% TUJ1+/Hb9-GFP+ 
Singh Roy et al. 
(2005) 
ESCs and iPSCs 
EB RA and SHH agonist 
iPSCs 



















69.5 ± 11.2% HB9+/CHAT+/TUJ1+ 
78.3 ± 3.5% ISL1+ 
iPSCs 
51.6 ± 5.7% HB9+/TUJ1+ 
65.4 ± 5.1% ISL1+ 
ESCs and iPSCs 
(Hb9::(E)GFP) 




59.1 ± 7.07% OLIG2+/SOX3+ 
28.2 ± 5.7% ISL1+/TUJ1+ 
iPSCs 
57.6% ± 9.88% OLIG2+/SOX3+ 









Amoroso  et al. 
(2013) 
83 ± 1% TUJ1+ 
<29 ± 4% HB9-GFP+ 
98 ± 0% HB9-GFP+/TUJ1+ 
30 ± 6% ISL1+/HB9-GFP+ 
16 ± 5% HB9+/HB9-GFP+ 
37 ± 2% ISL1+/HB9+/HB9-GFP+ 







PUR, RA and 
SB431542 
ESCs 






























NOG, RA and SHH 
Human 






Neuronal phenotypes, species, starting cell types, culture methods, chemical driving factors 
and representative phenotypic markers that have been used to assess the differentiation 
efficiency and culture homogeneity are broadly summarized. + indicates the percentage of 
cells in the population that stained positive for a certain marker. Abbreviations: 5-HT, 
serotonin (5-hydroxytryptamine); A83-01, TGF-β kinase/activin receptor-like kinase 
inhibitor; ACTB, actin beta/beta-actin; BF1, brain factor 1/forkhead box protein G1 
(FOXG1); BIO, GSK3β inhibitor 6-bromoindirubin-3'-oxime; BMPRIA-Fc, bone 
morphogenetic protein receptor 1a-fragment crystallizable; BRN2, brain-specific 
homeobox/POU domain protein 2 (POU3F2);; CALB1, calbindin 1; CHAT, choline o-
acetyltransferase;  CHIR99021, GSK3β inhibitor; CTIP2, b-cell CLL/lymphoma 11b 
(BCL11B)/ COUP-TF-interacting protein 2 (COUP-TFII); DKK1, dickkopf-1; DLX2, distal-
less homeobox 2; DMH-1, dorsomorphin homolog 1; DOR, Dorsomorphin; dsRed, 
discosoma sp. red fluorescent protein; EB, embryoid body; EGF, epidermal growth factor; 
EGFP, enhanced green fluorescent protein; ePet, enhancer of the mouse Pet-1 (human FEV) 
gene; ESCs, embryonic stem cells; FGF10, fibroblast growth factor 10; FGF2, fibroblast 
growth factor 2/basic fibroblast growth factor (bFGF); FGF4, fibroblast growth factor 4; 
FGF8, fibroblast growth factor 8; FGF8b, fibroblast growth factor 8 isoform b; FOXA2, 














decarboxylase isoform 65/67 (GAD2/1); GFP, green fluorescent protein; GIRK2, G protein-
activated inward rectifier potassium channel 2 (KCNJ6); HB9, homeobox HB9/motor neuron 
and pancrease homeobox 1 (MNX1); Hh-Ag1.3, small molecule agonist of SHH signalling; 
iPSCs, induced pluripotent stem cells; ISL1, ISL LIM homeobox 1; ISL1/2, ISL LIM 
homeobox 1/2; LDN193189, selective BMP signalling inhibitor; Lefty-1, left-right 
determination factor 1; Lefty-2, left-right determination factor 2; LHX6, LIM homeobox 6; 
LMX1A, LIM homeobox transcription factor 1 alpha; MAP2, microtubule-associated protein 
2; MAP2ab, microtubule-associated protein 2ab; MEF, mouse embryonic fibroblast; MS-5, 
stromal cell line derived from irradiated murine bone marrow cultures; NKX2-1, NK2 
homeobox 1; NOG, Noggin; NURR1, nuclear receptor related 1 protein; OLIG2, 
oligodendrocyte transcription factor 2; PA6, stromal cell line derived from newborn calvaria 
tissue of the C57BL/6 mice; PUR, purmorphamine; PV, parvalbumin; RA, retinoic acid; 
RUES1-EGFP, human ESC line expressing EGFP; SAG, smoothened agonist; SB431542, 
transforming growth factor beta inhibitor; SHH, sonic hedgehog; SHH-C24II, recombinant 
human SHH; SHH-C25II, recombinant mouse SHH; SMAD, transcription factor and member 
of the BMP and TGF-β signalling pathways; Sox1, SRY box 1; SOX3, SRY box 3; SST, 
somatostatin; SYN1, synapsin 1; TAU, microtubule-associated protein tau (MAPT); TBR1, 
T-box brain 1; TdT, tandem dimer tomato red fluorescent protein; TH, tyrosine hydroxylase; 
TPH, tryptophan hydroxylase; TPH2, tryptophan hydroxylase 2; TUJ1, neuron-specific class 
III beta-tubulin (TUBB3); VGLUT1, vesicular glutamate transporter 1; VGLUT2, vesicular 














Table 2. Transcription factor-mediated neuronal reprogramming protocols in vitro per 
neuronal phenotype. 

















Ascl1, Brn2 and 
Myt1l 
DOX 




Astrocytes Monolayer Ngn2 None 
70.2 ± 6.3% TUJ1+ 




ESCs Monolayer Ngn2 None <40% TUJ1+ 






(Tau::EGFP) and  
ESCs 
Monolayer Ascl1 DOX 
Mouse embryonic fibroblasts 






ESCs and iPSCs 
Monolayer 









17 ± 8% TBR1+/TUJ1+ 
Postnatal fibroblasts 
81 ± 17% TBR1+/TUJ1+ 





Zhang et al. 
(2013) 
±80% MAP2+ 



























Addis et al. 
(2011) 
35.1 ± 1.5% TUJ1+ 
50.9 ± 3.3% TH+/TUJ1+ 
18.2 ± 1.5% TH+ 
Fibroblasts 
14.9 ± 2.3% TUJ1+  





































 ±10% TH+/TUJ1+/MAP2+ 
Pfisterer et al. 
(2011) 
iPSCs Monolayer 
Ascl1, Lmx1a and 
Nurr1 
DOX 
Fetal fibroblast-derived iPSCs  
Theka et al. 
(2013) 
51 ± 4% TUJ1+ 
























Ascl1, Brn2, Dlx1, 
Dlx2, Lbx1, Lhx1, 
Lhx2, Myt1l, 
Pax2, Pitx2 and 
Pft1a 











35.9 ± 13.0% TUJ1+ 







and human iPSCs 
Monolayer 
Ascl1, Dlx5, Bf1, 












































58.4 ± 4.2% TUJ1+ 
±60% MAP2ab+ 
61 ± 15% TPH+/MAP2ab+  



















Mouse ESCs EB 
Isl1, Lhx3, Ngn2 
and Phox2a 
DOX 
Ngn2, Isl1 and Lhx3  
Mazzoni et 
al. (2013) 
99.82 ± 0.17% HB9+/ISL1+ 
0.24 ± 0.28% PHOX2B+/ISL1+ 
Ngn2, Isl1, Phox2a 
0.11 ± 0.11% HB9+/ISL1+ 





















Myt1l, Lhx3, Isl1, 




Son et al. 
(2011) 











Hester et al. 
(2011) 



















Mong et al. 
(2014) 
17.9% TH+/PHOX2A+/TUJ1+ 
Neuronal phenotypes, species, starting cell types, culture methods, transcription factors, 
chemical driving factors and representative phenotypic markers that have been used to assess 
the differentiation efficiency and culture homogeneity are broadly summarized. + indicates 
the percentage of cells in the population that stained positive for a certain marker. 
Abbreviations: 5-HT, serotonin (5-hydroxytryptamine); A83-01, TGF-β kinase/activin 














brain factor 1/forkhead box protein G1 (FOXG1); BMP5, bone morphogenic protein 5; 
BMP7, bone morphogenic protein 7; Brn2, brain-specific homeobox/POU domain protein 2 
(POU3F2); CALB1, calbindin 1; CD4, cluster of differentiation 4; CHAT, choline o-
acetyltransferase; CHIR99021, GSK3β inhibitor; Dlx1, distal-less homeobox 1; Dlx2, distal-
less homeobox 2; Dlx5, distal-less homeobox 5; DOX, doxycycline; dsRed, discosoma sp. red 
fluorescent protein; EGFP, enhanced green fluorescent protein; En1, homeobox protein 
engrailed 1; ESCs, embryonic stem cells; FEV, ETS transcription factor (PET1); FGF2, 
fibroblast growth factor 2/basic fibroblast growth factor (bFGF); FGF8, fibroblast growth 
factor 8; FGF8b, fibroblast growth factor 8 isoform b; FOXA2, forkhead box protein A2; 
GABA, γ-aminobutyric acid; GAD65/67, glutamic acid decarboxylase isoform 65/67 
(GAD2/1); GAD67, glutamic acid decarboxylase isoform 67 (GAD1); GATA2, GATA 
binding protein 2; GCaMP3, a GFP-based calcium sensor for imaging calcium dynamics; 
GFP, green fluorescent protein; GIRK2, G protein-activated inward rectifier potassium 
channel 2 (KCNJ6); HB9, homeobox HB9/motor neuron and pancrease homeobox 1 
(MNX1); Hh-Ag1.3, small molecule agonist of SHH signalling; hp53shRNA, human p53 
small hairpin RNA; iPSCs, induced pluripotent stem cells; ISL1, ISL LIM homeobox 1; 
Lbx1, ladybird homeobox 1; LDN193189, selective BMP signalling inhibitor; Lhx1, LIM 
homeobox 1; Lhx2, LIM homeobox 2; Lhx3, LIM homeobox 3; Lhx6, LIM homeobox 6; 
Lmx1a, LIM homeobox transcription factor 1 alpha; LMX1B, LIM Homeobox transcription 
factor 1 beta; MAP2, microtubule-associated protein 2; MAP2ab, microtubule-associated 
protein 2ab; Myt1l, myelin transcription factor 1 like; NEUROD1, neurogenic differentiation 
1; NGN2, neurogenin 2; NKX2-2, NK2 homeobox 2; NOG, Noggin; NURR1, nuclear 
receptor related 1 protein; Pax2, paired box 2; PD0332991, cyclin-dependent kinase 4/6 
inhibitor; Pft1a, pancreas specific transcription factor 1a; PHOX2A, paired-like homeobox 2a; 














homeodomain 3; PV, parvalbumin; RA, retinoic acid; SB431542, transforming growth factor 
beta inhibitor; SHH, sonic hedgehog; Sox2, SRY box 2; SST, somatostatin; SYN1, synapsin 
1; Tau, microtubule-associated protein tau (MAPT); TBR1, T-box brain 1; TH, tyrosine 
hydroxylase; TPH, tryptophan hydroxylase; TPH2, tryptophan hydroxylase 2; TUJ1, neuron-
specific class III beta-tubulin (TUBB3); VACHT, vesicular acetylcholine transporter; VGAT, 
vesicular GABA transporter; VGLUT1, vesicular glutamate transporter 1; VGLUT2, 















Table 3.  Epigenetic-based neuronal conversion approaches in vitro per neuronal phenotype. 
Chemical compounds targeting chromatin remodelling proteins 













































































Cheng et al. 
(2015a) 
Epigenetic editing 








































Ascl1, and Myt1l 





None DOX 7% TUJ1+ 
Chavez  et al. 
(2015) 
RNAi 










markers (% cells) 
References 




siRNA-REST None FGF2 and RA 
<80% TUJ1+ 
<80% MAP2+ 





EB and  
co-culture 
(PA6) 
miR-132-ASOs None None 
>25% TH+/MAP2+ 
70% TH+/TH-GFP+ 
Yang et al. 
(2012) 
ESCs EB miR-133b-ASOs None FGF2 20% TH+/PITX3+ 
Kim et al.  
(2007) 














Stappert  et al. 
(2013) 











DOX and RA 
Postnatal fibroblasts 













































NOG and DOX 
Postnatal fibroblasts 
Ambasudhan 









Human Fibroblasts Monolayer 
miR-9/9*, 
miR-124 (Bcl-
xL) and VPA 






Neuronal phenotypes, species, starting cell types, culture methods, epigenetic factors, 
transcription factors, chemical driving factors and representative phenotypic markers that 
have been used to assess the differentiation efficiency and culture homogeneity are broadly 
summarized. + indicates the percentage of cells in the population that stained positive for a 
certain marker. Abbreviations: ASCL1, achaete-scute homolog 1 (MASH1/HASH1); ASOs, 
anti-sense oligonucleotides; Bcl-xL, b-cell lymphoma-extra large; BF1, brain factor 
1/forkhead box protein G1 (FOXG1); BIX-01294, histone-lysine methyltransferase inhibitor; 














acetyltransferase; CHIR99021, GSK3β inhibitor; CTIP2, b-cell CLL/lymphoma 11b 
(BCL11B)/ COUP-TF-interacting protein 2 (COUP-TFII); DCX, doublecortin; DLX1, distal-
less homeobox 1; DLX2, distal-less homeobox 2; DOX, doxycycline; EB, embryoid body; 
EGFP, enhanced green fluorescent protein; ESCs, embryonic stem cells; FGF2, fibroblast 
growth factor 2/basic fibroblast growth factor (bFGF); FGF8, fibroblast growth factor 8; 
FGF8b, fibroblast growth factor 8 isoform b; GABA, γ-aminobutyric acid; GAD67, glutamic 
acid decarboxylase isoform 67 (GAD1); GFAP, glial fibrillary acidic protein; GFP, green 
fluorescent protein; gRNAs, guide RNAs; iPSCs, induced pluripotent stem cells; IRES, 
internal ribosome entry site; LDN193189, selective BMP signalling inhibitor; Li2CO3, 
lithium carbonate; LiCl, lithiumchloride; LIF, leukemia inhibitory factor; MAP2, 
microtubule-associated protein 2; MYT1L, myelin transcription factor 1 like; NaB, sodium 
butyrate; NES, nestin; NEUN, neuronal nuclei antigen; NEUROD1, neurogenic 
differentiation 1; NEUROD2, neuronal differentiation 2; NGN2, neurogenin 2; NPCs, neural 
precursor cells; PA6, stromal cell line derived from newborn calvaria tissue of the C57BL/6 
mice; PAX6, paired box 6; PITX3, paired-like homeodomain 3; RA, retinoic acid; REST, 
RE1-silencing transcription factor; RFP, red fluorescent protein; SAG, smoothened agonist; 
SB431542, transforming growth factor beta inhibitor; SHH, sonic hedgehog; siRNAs, small 
interfering RNAs; Sox1, SRY box 1; SOX2, SRY box 2; SYN1, synapsin 1; t2PCPA, trans-2-
phenyl-cyclopropylamine hydrochloride; Tau, microtubule-associated protein tau (MAPT); 
TBR1, T-box brain 1; TH, tyrosine hydroxylase; Trp53, tumor protein p53; TSA, trichostatin 
A; TUJ1, neuron-specific class III beta-tubulin (TUBB3); VGAT, vesicular GABA 
transporter; VGLUT1, vesicular glutamate transporter 1; VP64-dCas9-VP64, dCas9 with N-
terminal and C-terminal VP64 transactivation domains; VP64-p65-Rta-dCas9, dCas9-based 
transcriptional activator containing VP64, p65 and Rta; VPA, valproic acid. 
AC
CE
PT
ED
 M
A
US
CR
IP
T
